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Abstract 
Investigation of the genetics of acute myeloid leukaemia (AML) has revealed the underlying 
basis of the disease and led to targets for therapy. High-resolution single nucleotide 
polymorphism (SNP) arrays detected regions of loss of heterozygosity and DNA copy number 
changes, augmenting the results of conventional cytogenetic analysis in AML. Fifteen out of 72 
(20%) primary AML samples exhibited large regions of homozygosity that could not be 
accounted for by visible chromosomal abnormalities in the karyotype. Further analysis 
confirmed that these patterns were due to partial uniparental disomy (UPD). Remission marrow 
was available from five patients showing UPD in their leukemias, and in all cases the 
homozygosity was found to be restricted to the diagnostic leukemic clone. These cryptic non- 
random chromosomal abnormalities are characteristic of mitotic recombination. In 7 of 13 cases 
with UPD, concurrent homozygous mutations were identified at four distinct loci (WTI, FLT3, 
CEBPA, and RUNXI). This implies that mutation precedes mitotic recombination which acts as 
a "second hit" responsible for removal of the remaining wild-type allele. Clonal evolution from 
heterozygous to homozygous mutations by mitotic recombination would provide a mechanism 
for relapse of AML. Analysis of 27 paired diagnostic and relapsed AML samples demonstrated 
newly acquired segmental UPDs at relapse in 11 AML samples (40%). Six were segmental 
UPDs of chromosome 13q, which led to a change from heterozygosity to homozygosity for 
internal tandem duplication of FLT3. Three further AML samples had evidence of acquired 
segmental UPD of 13q in a subclone of the relapsed leukemia. One patient acquired segmental 
UPD of 19q which led to homozygosity for a CEBPA mutation 207 C-'T. Finally, a single 
AML patient acquired segmental UPD of chromosome 4q, for which the candidate gene is 
unknown. In conclusion, the acquisition of segmental UPD and the resulting homozygous 
mutation is a common event associated with relapse of AML. 
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Chapter 1 
Chapter 1 
Introduction 
Acute myeloid leukaemia (AML) is a malignant proliferation of poorly differentiated myeloid 
cells, or blast cells. It is characterised by the accumulation of these cells in bone marrow and 
usually blood, often leading to cytopenias in other myeloid lineages. Blasts can also move into 
extracellular tissues causing splenomegaly, hepatomegaly and sometimes lymphadenopathy. 
The leukaemic cells have been described in many other tissues as chloromas or granulocytic 
sarcomas and in the central nervous system. Untreated the disease is uniformly fatal. In England 
and Wales, the annual incidence of myeloid leukaemia for all ages for 2004 was 6.0 and 4.7 per 
100,000 population for males and females respectively (Office for National Statistics 2005, 
Office for National Statistics 2006). This incidence has been increasing for males having been 
only 5.5 per 100000 in 1992, most probably because the elderly population is expanding. For 
males aged 80-84 years the incidence has increased from 36.4 per 100000 in 1992 to 40.7 per 
100000 in 2004, although the age standardised rate has remained unchanged over the last 10 
years. AML is becoming an increasingly important disease of the elderly. 
The initial descriptions of leukaemia in 1845 by Craigie, Bennett and Virchow were of 
suppuration or pus in the blood (Bennett 1845, Craigie 1845, Piller 2001). Bennett particularly 
noted that the alteration of the blood had occurred in the absence of inflammation and was able 
to give descriptions and drawings of white cells from light microscopy. By 1849, Virchow had 
described three cases and distinguished them into splenic and lymphatic forms due to the 
presence or absence of splenomegaly. Acute leukaemia was first used as a term in 1857 by 
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Nikolaus Friedrich, because of the short period between presentation and death. In 1868, 
Neumann described the origin of leukaemia as from the bone marrow and later added 
myelogenous leukaemia to the classification. It was the discovery of aniline dyes (by William 
Henry Perkin in 1856) that led Paul Ehrlich to develop stains that identified myeloid and 
lymphoid cells from their cytoplasmic and nuclear structures. He maintained that leukaemia was 
a disease of the haematopoietic system. Further evidence for this came from the identification of 
myeloblasts and lymphoblasts as immature cells in the granulocytic and lymphocytic series by 
Naegli in 1900. 
During the twentieth century, progress in the diagnosis and treatment of AML 
accelerated due to improved cytological classification with cytochemistry, and the advent of 
chemotherapy inducing meaningful remissions. Subsequently, cytogenetics and molecular 
biology have greatly improved our understanding of the disease and refined the diagnostic 
classifications. 
1.1 Aetiology 
AML may be divided into de novo and secondary types. The causes of de novo AML 
are poorly understood. Many epidemiological studies have looked at potential agents 
predisposing to de novo AML. Because of the difficulties of confounding variables, subjective 
answers and the difficulties in finding corresponding control groups, the relative risk of 
leukaemia identified by these case control studies are slight. For example, there are studies into 
potentially carcinogenic agents such as hair dyes where there is a trend towards an association 
or a borderline significant association with AML (odds ratio 1.6,95% confidence interval (CI) 
1.1-2.4) (Mele, et a! 1994, Rauscher, et a! 2004). Another case control study found cigarette 
smoking associated with AML M2 (odds ratio 2.3,95% CI 1.1-4.4) (Pogoda, et a! 2002). As for 
all epidemiological case control studies, the real significance of these results will only be known 
if they can be replicated in other populations. 
For secondary AML clear aetiological agents have been described. As demonstrated 
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after the Hiroshima and Nagasaki bombs (Folley, et al 1952), irradiation can lead to AML and 
myelodysplastic syndrome (MDS). The risk of AML was correlated inverse square of the 
distance from the explosion, with the risk rising rapidly with doses of radiation greater than 0.5 
Gy. The incidence of AML was maximal 7 years after the explosions, but an increased 
incidence of AML continued up to 40 years later (Schull 1998). Latterly, there is also evidence 
for an increased incidence of AML in those exposed after the Chernobyl disaster (Gluzman, et 
al 2006). Radiotherapy treatment predisposes to AML/MDS (Michels, et al 1985), although 
most cancer patients are also exposed to cytotoxic chemotherapy that is mutagenic. Patients 
with polycythaemia vera (PV) treated with phosphorus-32 have an increased risk of AML, 
complicated by PV also increasing the risk of developing leukaemia (Parmentier 2003). A 
clearer indication of the risks of radiotherapy was given by a disease not associated with 
leukaemia, ankylosing spondylitis. It was treated with irradiation in the 1930s to the 1950s, but 
this population was found to have an increased incidence of leukaemia, with a dose-response 
relationship (Court-Brown and Doll 1957). 
Chemical exposure can also lead to AML, of which the most important organic 
compound is benzene (Hayes, et al 1997). Studies of Chinese industrial workers show a dose 
dependent increase in levels of MDS and AML in those exposed to benzene, with a relative risk 
up to 7 times, in those exposed to 25 parts per million of benzene (Hayes, et al 1997). Two 
groups of cytotoxics are particularly associated with AML. Alkylating agents are associated 
AML/MDS with poor risk cytogenetics, such as deletion of chromosome 5,5q, 7 or 7q, as is 
observed after high dose therapy (HDT) with cyclophosphamide (Micallef et al 2000). In this 
study, after a median follow up of 6 years, 14% of 230 patients developed AML/MDS. 
However, retrospectively, many of these patients had the same cytogenetic abnormalities in a 
few cells prior to HDT, suggesting that chemotherapy given up to that point (which frequently 
included chlorambucil) had contributed to the development of AML. The other major group of 
cytotoxics that cause AML are topoisomerase II inhibitors, such as etoposide. These tend to be 
associated with balanced translocations, e. g. those involving the MLL gene at chromosome 
11g23 (Super, et al 1993). In patients with acute promyelocytic leukaemia (APML) that is 
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secondary to topoisomerase II inhibitors, the t(15; 17) breakpoint between PML and RARA 
occurs at sequence hotspots that are targeted by etoposide (Mistry, et al 2005). 
AML can occur secondary to azathioprine use, as noted after solid organ transplants 
(Offman, et a! 2004). DNA damage caused by azathioprine is due to mismatch repair, where an 
incorrect nucleotide is inserted during DNA replication. The AML cells of these patients are 
defective in mismatch repair as demonstrated by microsatellite instability (Offinan, et a! 2004). 
AML is also associated with a number of other haematological diseases. MDS has a 
close association, with high-risk subtypes frequently transforming into AML. Many AML 
patients have trilineage dysplasia, and the distinction between AML and MDS is arbitrarily set 
with more than 20% myeloblasts in the bone marrow defining AML. Previously, the French 
American British classification (FAB) defined blasts of 20-30% as a subtype of MDS, known as 
refractory anaemia with excess blasts in transformation (RAEB-T) (Bennett, et a! 1982). Factors 
influencing transformation to AML are part of the international prognostic scoring system 
(IPSS) (Greenberg, et al 1997). These include cytogenetic abnormalities, percentage of bone 
marrow myeloblasts and number of lineages with cytopenias. 
Myeloproliferative diseases (MPDs), particularly chronic myeloid leukaemia (CML), 
can also transform into AML. CML transforms from a chronic phase into a blast crisis that 
resembles AML or acute lymphoblastic leukaemia (ALL), with some passing through an 
accelerated phase. CML is characterised by the Philadelphia chromosome, t(9; 22) (Nowell and 
Hungerford 1960), that encodes the fusion protein BCR/ABL, the underlying genetic defect. 
Myelosuppressive treatment, e. g. with hydroxycarbamide, controls the high white blood cell 
and platelet count, but does not affect the number of Philadelphia positive cells. With 
hydroxycarbamide, 70% of patients transform to accelerated phase or blast crisis over 6 years 
(Hehlmann, et al 1993). Use of imatinib, a tyrosine kinase inhibitor targeting BCR/ABL, has 
reduced progression to accelerated phase or blast crisis to just 10% at 6 years (Druker, et al 
2006). This has become the paradigm for targeted therapy in cancer, and demonstrates that 
targeting the underlying genetic defect may treat or prevent leukaemia. 
Essential thrombocythaemia, and polycythaemia vera are frequently treated with 
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cytotoxic agents such as hydroxycarbamide, to reduce the platelet count or the packed cell 
volume. It has been difficult to disentangle whether the disease or the treatment predisposes to 
AML, although some of the treatments used historically, such as phosphorus-32 or busulphan, 
are leukaemogenic (Harrison 2005). About 20% of patients with myelofibrosis also transform 
into AML over 10 years, with a higher risk for those with a haemoglobin concentration of less 
than l Og/dl, constitutional symptoms or circulating blasts (Cervantes, et al 1998). 
1.2 Genetic Predisposition 
A small number of patients with AML are known to be associated with germline 
genetic abnormalities (Owen, et a! 2008). Individuals with trisomy 21 or Down syndrome have 
an increased risk of several myeloid disorders, including transient abnormal myelopoiesis 
(TAM), MDS and AML, especially acute megakaryocytic leukaemia (AMKL) (Vyas and 
Roberts 2006). Patients with TAM and AMKL have mutations in GATA-1, a transcription factor 
involved in erythropoiesis and megkaryopoiesis (Ahmed, eta! 2004). 
Patients with neurofibromatosis (NF) and Noonan syndrome (NS) are predisposed to 
juvenile myelomonocytic leukaemia (JMML), AML and other malignancies (Lauchle, et al 
2006). They have mutations in NF1 and PTPNJ1 respectively, both of which cause deregulation 
of the RAS signalling pathway. The oncogene, RAS, encodes a GTPase that is downstream of 
several cytokine growth factors and induces proliferation. In JMML, there is increased RAS 
pathway activity due to heterozygous mutations in KRAS or PTPNI1, or homozygous mutations 
in NF1(Flotho, et al 2007). 
All patients with congenital bone marrow failure syndromes have an increased risk of 
AML e. g. Diamond-Blackfan Anaemia (Freedman 2000), and congenital neutropenia 
syndromes such as Schwachman-Diamond syndrome (Rosenberg, et al 2006). Patients with 
severe congenital neutropenia have a 13% risk of developing AML or MDS while on treatment 
with recombinant granulocyte colony stimulating factor (GCSF) (Dale, et al 2003). It is unclear 
whether it is the disease or the treatment that predisposes to leukaemia, as the patients did not 
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live long enough before the advent of treatment with GCSF, but interestingly those with cyclical 
and idiopathic neutropenia did not get leukaemia. 
Other inherited syndromes with defects in DNA repair such as Fanconi's anaemia (FA) 
or Bloom's syndrome are also associated with many cancers including AML. Patients with FA 
have chromosomal breaks due to mutations in genes in the FA pathway involved in homologous 
double-strand DNA repair. They have an incidence of AML and MDS between 10 to 15% 
(Mathew 2006). Bloom syndrome involves mutations of BLM helicase involved in the repair of 
double strand DNA breaks by homologous recombination. A registry of Bloom syndrome 
patients gives an incidence of AML of about 20% (German 1997). 
There are also reports of familial AML or MDS, some associated with deletions of 
chromosome 5q or chromosome 7/7q, but no causative gene has been found in these cases (Gao, 
et at 2000, Grimwade, et at 1993, Hess 2001). Inherited single gene mutations have been 
described in familial AML involving CEBPA (Smith, et at 2004b). This is an inherited 
heterozygous mutation, where the affected family members have acquired a second somatic 
mutation at the time of developing AML in childhood or early adulthood. Familial platelet 
disorder with AML is an autosomal dominant inherited disorder that involves a heterozygous 
mutation and haploinsufficiency of RUNXI (Song, et at 1999). The patients have a low platelet 
count with a bleeding tendency, and may develop AML in the first to the 6`" decade. 
There is evidence from case control studies for inherited polymorphisms predisposing 
to AML, particularly in genes encoding metabolic enzymes and DNA repair proteins. The 
numbers of patients studied are relatively small but significant effects have been observed for 
predisposition to therapy related AML from DNA repair genes involved in the repair of double 
strand breaks, e. g. polymorphisms in the 5' untranslated region of HLXI and RAD51 increased 
the relative risk of therapy related AML by 9.5 times (95% CI, 2.22-40.64) (Jawad, et at 2006). 
The same polymorphism of RAD51 associated with a non-synonymous polymorphism of 
XRCC3 also gave an increased risk (odds ratio, 8.11; 95% CI, 2.22-29.68) (Seedhouse, et at 
2004). XRCCJ is involved in base excision repair, and a non-synonymous polymorphism is 
associated with a reduced risk of developing therapy related AML (odds ratio 0.44; 95% 
18 
Chapter 1 
confidence interval, 0.20-0.93) (Seedhouse, et al 2002). As with all genetic association studies, 
replication in other populations will show how robust these associations really are (Kuptsova, et 
a! 2007). 
1.3 Diagnosis and Classification 
AML typically presents with bone marrow failure and high white blood cell count due 
to the accumulation of myeloblasts. The symptoms are very variable but include fatigue and 
lethargy due to anaemia, bleeding due to thrombocytopenia and severe bacterial infection due to 
neutropenia. Tissue infiltration may result in organomegaly, particularly with monocytic and 
monoblastic leukaemias. The diagnosis of acute leukaemia is made on light microscopy of the 
blood smear and further classification of AML is based on morphology, immunophenotype and 
cytogenetics. As for all diseases, an accurate diagnosis is required to ensure the correct 
treatment is given in the light of the patient's likely prognosis. For AML, the main differential 
diagnosis is ALL, and subsequent subclassification of AML identifies the likely prognosis and 
possible lines of treatment. 
1.4 Morphology 
Morphological analysis is carried after staining the cells with a Romanowsky type stain and 
further elucidated using cytochemical techniques to look for myeloperoxidase (MPO) positive 
granules and non-specific esterases (NSE) to identify vesicles found in monocytic lineage cells. 
AML is characterised by the differentiation of the blast cells into various subtypes by the FAB 
classification (Table 1.1) (Bennett, et al 1976, Bennett, et al 1985). They are broadly divided 
into myeloid, monocytoid, erythroid and megakaryocytoid forms. The subtypes are generally 
treated the same, except for AML M3 or APML which is associated with t(15; 17), producing 
the PML-RARA fusion protein (Goddard, et al 1991). This leukaemia is associated with 
hypofibrinogenemia leading to bleeding, which previously gave the condition a high mortality. 
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However, the promyelocytes readily differentiate with all-trans retinoic acid (ATRA), which is 
used as part of the treatment for APML. Several other morphological variants are associated 
with cytogenetic abnormalities, for example t(8; 21) is associated with AML M2, and inv(16) 
with AML M4 with eosinophils (M4Eo). Other FAB types also have associations e. g. AML M6 
often occurs in the context of MDS (Bain 1999). The importance of other factors than 
morphology in the classification of AML, particularly molecular cytogenetics and types of 
secondary AML, led to the development of the World Health Organisation (WHO) 
classification (Table 1.1) (Brunning, et a! 2001). 
Antibodies to the myeloid cell markers cytoplasmic MPO, CD33, CD13 and CD 117 are 
used to confirm the diagnosis (Bain, et a! 2002). By using flow cytometry, several hundred or 
thousand cells can be analysed in a short space of time. Some FAB types require further 
immunophenotyping to make the diagnosis i. e. M6 and M7. Acute erythroblastic leukaemia 
(M6) expresses glycophorin A, an erythroid cell marker but has a characteristic morphology 
because of the presence of megaloblastic looking blast cells. Acute megakaryocytic leukaemia 
(M7) expresses CD41, CD42 and CD61, although the morphology is often undifferentiated. 
AML MO has by definition an undifferentiated morphology, so identification of the myeloid 
antigens and the absence of lymphoid antigens is required for diagnosis. These three FAB types 
all have a relatively poor prognosis in adults (Colita, et al 2001, Oki, et al 2006, Roumier, et al 
2003). 
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Table 1.1 Classifications ofAML. 
FAB Classification: 
MO: Undifferentiated 
M1: AML without maturation 
M2: AML with maturation 
M3: Acute promyelocytic leukaemia 
M4: Myelomonocytic leukaemia 
M5: Monocytic leukaemia 
M6: Erythroleukaemia 
M7: Megakaryoblastic leukaemia 
WHO Classification: 
I. AML with recurrent cytogenetic 
translocations 
AML with t(8; 21)(q22; q22); RUNXI (AMLI 
or CBFA2)1 R UNXI T1(ETO or MTG8) 
Acute promyelocytic leukaemia [AML with 
t(l5; 17)(g22; g12) and variants; PMLJRAR] 
AML with abnormal bone marrow 
eosinophils [inv(16)(p13g22) or 
t(16; 16)(p13; g22) CBFB/MYHJI] 
AML with 11g23 (MLL) abnormalities 
II. AML with multilineage dysplasia 
With prior myelodysplastic syndrome 
Without prior myelodysplastic syndrome 
III. AML and myelodysplastic syndrome, 
therapy-related 
Alkylating agent-related 
Epipodophyllotoxin-related 
Other types 
IV. AML not otherwise categorized 
AML minimally differentiated 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monocytic leukaemia 
Acute erythroid leukaemia 
Acute megakaryocytic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
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1.5 Cytogenetics 
Not only are recurrent cytogenetic abnormalities associated with some morphological subtypes, 
but they are also the most important biological prognostic markers in AML. APML with 
t(15; 17) and those with core binding factor (CBF) translocations i. e. t(8; 21) and 
inv(16)(g13g22), have the best prognosis, with a 50-60% 5 year survival (Grimwade, et al 
1998) (Table 1.2). Other cytogenetic abnormalities correspond to poor prognosis i. e. deletions 
of chromosome 5,5q or 7, abnormalities of 3q, or a complex karyotype (more than 4 
abnormalities) with about 10-15% 5 year survival. However, these make up only about 30% of 
AML. Most other cytogenetic abnormalities have an intermediate prognosis, including about 
40% of patients with AML that have no karyotypic changes at all. Never the less, these 
prognostic abnormalities allow a refinement in the classification. The WHO classification uses a 
combination of cytogenetic abnormalities and the FAB classification (Table 1.1) in an attempt 
to create a more clinically relevant classification. Several large cohort clinical randomised trials 
have used cytogenetic profiles to risk stratify patients (Byrd, et al 2002, Grimwade, et al 1998, 
Slovak, et al 2000) (Table 1.2). There are minor variations in the definitions of good, 
intermediate and poor risk, with some studies including rare abnormalities that have a poor 
prognosis e. g. t(6; 9), and others suggesting that some translocations involving MLL at 11g23 
have a poor prognosis. These trials also disagree as to the prognosis of some cytogenetic 
abnormalities, e. g. del(5q) is defined as poor risk by the MRC and SWOG/ECOG, but is of 
intermediate risk according to CALGB (Table 1.2). 
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Table 1.2 Cytogenetic risk group definitions. 
MRC (Grimwade, et al 
1998) 
Good t(15; 17), t(8; 21), 
inv(16) or t(16; 16) 
Standard / 
Intermediate 
Poor 
Neither good nor poor 
-5 or del(5q), -7, 
abnormalities of 3q, 
complex karyotype (>4 
abnormalities) 
SWOG/ECOG 
(Slovak, et al 2000) 
inv(16)/t(16; 16)/del (16 
q), t(15; 17) 
with/without secondary 
aberrations; 
t(8; 21) lacking del(9q) 
or complex karyotypes 
Normal, +8, +6, -Y, 
del(12p) 
del(5q)/-5, -7/del(7q), 
abn 3q, 9q, l lq, 20q, 
21q, 17p, t(6; 9), t(9; 22) 
and complex 
karyotypes (>_3 
unrelated 
abnormalities) 
CALGB (Byrd, et al 
2002) 
t(8; 21), inv(16) or 
t(16; 16)* 
Del(9q), normal 
karyotype, 
-Y, del(5q), del(7q), 
t(9; 11), +11, del(11 q), 
abn(12p), +13, 
del(20q), +21 
Complex karyotype 
(>_3 abnormalities), 
inv(3), t(6; 9), t(6; 11), - 
7, +8 sole, +8 with one 
abnormality, 
t(11; 19)(g23; p 13.1) 
*Did not include t(15; 17) in analysis 
Abbreviations: MRC, Medical Research Council; SWOG/ECOG, Southwest Oncology Group/ 
Eastern Cooperative Oncology Group; CALGB, Cancer and Leukaemia Group B. 
1.6 Pathophysiology 
1.6.1 Clonality 
The clonal nature of leukaemia, including AML is now beyond doubt. Recurrent 
cytogenetic abnormalities, as first described for the Philadelphia chromosome in chronic 
23 
Chapter 1 
myeloid leukaemia, gave an indication that leukaemia was a clonal disorder (Nowell and 
Hungerford 1960). In AML, there are many recurrent clonal cytogenetic abnormalities as 
discussed above. Clonality has also been demonstrated using X chromosome inactivation 
patterns (XCIPs) e. g. using glucose 6 phosphate dehydrogenase alleles (Fialkow, et al 1967) or 
HUMARA, the human androgen receptor locus (Gale, et al 1993). Although it is normal for X 
chromosomes from either parent to inactivate in equal number, under physiological conditions 
one chromosome can be inactivated more frequently than the other, e. g. due to aging. This 
skewing can be demonstrated by examining at the XCIPs of T lymphocytes. Therefore, to 
determine the clonality of the leukaemia, the background XCIP must be assessed. Mutation 
analysis gives more reliable evidence of clonality. Gene sequencing has demonstrated acquired 
single gene defects in AML e. g. in tyrosine kinase genes such as FLT3. These mutations are 
only found in the leukaemic clone (Kottaridis, et a12001). 
Further studies have shown a likely stem cell origin for leukaemia, implying the whole 
clone is derived from a single stem cell (Bonnet and Dick 1997). These studies involve the 
transplantation of subsets of leukaemic cells into immune deficient transgenic mice (the non- 
obese diabetic severe combined immunodeficient or NOD-SCID mouse). Clonal subsets of 
human leukaemic cells sorted by flow cytometry with the immunophenotype CD34+ and CD38- 
, can be transplanted into NOD-SCID mice and after several weeks the human leukaemia is 
recapitulated in the mouse. Furthermore, the leukaemia can be flow sorted again based on the 
above immunophenotypic markers and transplanted to other NOD-SCID mice, demonstrating 
that the stem cells can self-renew. 
1.7 The function of genetic abnormalities in AML 
1.7.1 Translocations 
Many of the recurrent cytogenetic abnormalities described in AML are balanced 
24 
Chapter 1 
translocations. The breakpoints of these chromosomes are non-random double strand DNA 
breaks, within the exons of two genes of each chromosome. The break is in-frame, producing a 
new functional protein from the fusion of the two genes. The importance of fusion genes is that 
they are oncogenic, and are probably the underlying mutation in the development of the 
leukaemia. The identification of the fused genes has led to the discovery of novel oncogenes 
and functional studies of the translated fusion proteins have demonstrated their oncogenic 
potential (de The, et al 1990, Djabali, et al 1992). Many of the genes involved in translocations 
in AML are regulators of transcription, such as CBFs, retinoic acid receptor alpha (RARA) or 
the mixed-lineage leukaemia gene (MLL). All these genes are involved in normal 
haematopoiesis (Gilliland, et a! 2004). 
CBFs are heterodimeric complexes made from alpha and beta subunits. CBFbeta, 
encoded by CBFB, and CBFA2 encoded by RUNXI, interact and are required for normal 
haematopoiesis. During embryonic development in mice, RUNXI is expressed in 
haemangioblasts, and deficiency of either RUNXI or CBFB leads to a lack of erythropoiesis, 
myelopoiesis and fetal death (Okuda, et al 1996). RUNX family proteins share a conserved 128 
amino acid region, RHD, homologous to the Runt protein in Drosophila melanogaster (Mikhail, 
et al 2006). The RHD domain binds the alpha to the beta subunit, which then allows RHD to 
bind consensus DNA sequences in the promoter regions of several cytokines involved in 
haematopoiesis, including granulocyte-monocyte colony stimulating factor and interleukin-3 
(Otto, et al 2003). Both RUNXI and CBFB are involved in several translocations in AML and 
ALL. CBFB fuses with MYHI1 by the inv(16) translocation, and produces an acute 
myelomonocytic leukaemia with eosinophilic differentiation (AML M4Eo). MYHIJ encodes a 
smooth muscle heavy chain protein. In yeast cells, CBFB-MYH11 binds to RUNXI with other 
nuclear corepressors (NCoRs) e. g. mSin3A, and prevents transcription through a repression 
domain in MYH1I (Lutterbach, et al 1999). Additionally in mice, CBFB-MYH11 prevents 
normal haematopoiesis by inhibiting the CBF complex and preventing the differentiation of 
myeloid and lymphoid precursors (Kundu, et al 2002). The most common translocation 
involving RUNXI in AML is t(8; 21)(q22; q22), which creates a fusion with RUNXITI, another 
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transcription factor (also known as ETO or MTG8), and produces AML with mature myeloid 
blasts (AML M2). RUNXITI encodes a zinc finger nuclear protein homologous to the 
Drosophila nervy gene (Gelmetti, et at 1998). The fusion protein RUNX1-RUNXITI recruits 
NCoRs and histone deacetylases (HD) that prevent DNA transcription (Gelmetti, et at 1998, 
Wang, et at 1998). The RHD domain of the RUNX1 part of the fusion protein then targets 
cytokine promoter sequences for transcription repression, thus blocking myeloid and erythroid 
differentiation (Peterson and Zhang 2004). It would appear that CBF leukaemias have similar 
mechanisms for transcription repression, and they have other similarities, both having being 
associated with a relatively good prognosis and being associated with CKIT mutations (Paschka, 
et at 2006). 
The PMURARA fusion protein is found in 99% of APML, and usually arises from the 
translocation t(15; 17)(g22; g21) (de The, et at 1990, Goddard, et at 1991, Pandolfi 2001). A 
common motif between CBF leukaemias and RARA fusion leukaemias is their ability to reduce 
transcription through NCoRs and HDs. Retinoic acid receptors (RAR) interact with retinoid-X- 
receptors and NCOR2 (also known as SMRT), which then recruit HDs to repress transcription 
of target genes that have retinoic acid response elements (Chen and Evans 1995, Heinzel, et at 
1997). Interaction of RAR with its ligand, retinoic acid (RA), allows dissociation of the 
NCoR/HD complex, permitting transcription. PMURARA also binds RXR and NCoR/HD, 
leading to transcription repression that is reversed by pharmacological levels of RA (Grignani, 
et at 1998, Minucci and Pelicci 2007). At a cellular level, the effects of PML/RARA lead to a 
differentiation block at the promyelocyte stage, but RA allows neutrophil differentiation 
(Grignani, et at 1993). This leads to hyperleucocytosis due to an accumulation of differentiated 
neutrophils when APML is treated with ATRA. A rare form of APML involving the 
translocation t(11; 17), produces the fusion gene PLZF/RARA. It also binds NCoR and HD 
causing transcription repression, but has little or no response to RA (Grignani, et at 1998). 
MILL is a homologue of the Drosophila trithorax gene, required for embryonic and 
haematopoietic development (Ayton and Cleary 2001). Like trithorax, it regulates HOX gene 
expression in embryonic development, including haematopoietic development (Hess, et at 
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1997). MLL is very large, coding for a protein with 3,969 amino acids and is 430kD. It contains 
several different functional protein subunits that are formed by post-translational cleavage to 
produce large multimeric complexes (Nakamura, et a! 2002). An example of one of the subunits 
is the SET domain at the C terminal, which codes for a histone H3 lysine-4 methyltransferase 
that methylates histones at the promoter of HOXA9. MILL is the most promiscuous gene 
involved in translocations in acute leukaemia, with many different partner genes (DiMartino 
and Cleary 1999). The breakpoint of MLL is consistently between exons 5 and 8, leading to 
retention of motifs for DNA binding at the N terminal, but loss of the motifs involved in histone 
methylation at the C terminal. Histone modification is still important in the function of MLL 
fusion genes because the histone methylation gene, hDOTIL, is required for the MLL-AF10 
fusion protein to promote leukaemogenesis by targeting HOXA9 (Okada, et a! 2005). At least 
one of the functions of the N-terminal motifs in MLL fusion proteins is to interact with a known 
tumour suppressor gene (TSG), MEN], at HOX gene promoters, leading to leukaemogenesis in 
mice (Yokoyama, et a! 2005). These mechanisms lead to alterations in HOX gene expression 
in AML with MLL translocations, as has been observed using expression microarrays in primary 
AML samples (Debernardi, et a! 2003). 
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1.7.2 Single gene mutations 
Table 1.3 Common single gene mutations in AML 
Mutation Mutation location Predominant AML Reference 
and type subtypes 
RUNXI Runt domain, point AML MO (Roumier, et a! 2003) 
mutation 
MLL PTD NK, +11 (Rege-Cambrin, et a! 
2005, Whitman, et a! 
2007a) 
FL T3 JM region, ITD NK, t(15; 17), t(6; 9) (Kottaridis, et a! 2001) 
(Thiede, et a! 2002) 
Loop /TKD, point NK, inv(16) (Mead, et a! 2007) 
mutation 
NPMI Exon12,4bp insertion NK (Falini, et a! 2005) 
C-KIT Loop /TKD, point inv(16), t(8; 21) (Paschka, et a! 2006) 
mutation 
NRAS Codons 12,13 and 61, t(3; 5), inv3/t(3; 3), (Bowen, et a! 2005) 
point mutations inv(16) (Bacher, eta! 2006) 
KRAS Codon 61, point inv(16) (Bowen, et a! 2005) 
mutation 
WTI Exons 7-9 NK (King-Underwood, et 
a! 1996, Summers, et 
a! 2007) 
Abbreviations: NK, normal karyotype; PTD, partial tandem duplication; ITD, internal tandem 
duplication; JM, juxtamembrane; TKD, tyrosine kinase domain. 
Some of the genes involved in chromosomal translocations may also acquire mutations 
contributing to leukaemogenesis when there are no chromosomal rearrangements ( 
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Table 1.3). Acquired point mutations of RUNXI are found in undifferentiated AML (AML MO), 
and occasionally in other FAB types (Preudhomme, et al 2000, Roumier, et a12003, Smith, et 
a! 2005). Most are found in the Runt domain, involved in DNA binding. They lead to decreased 
DNA binding and sometimes decreased binding to CBFbeta (Matheny, et al 2007). Mouse 
models of these RUNX1 mutations cause abnormal haematopoiesis when the mutation 
homozygous, but some produce only a mild haematopoietic defect when heterozygous 
(Matheny, et a! 2007). In primary AML, these mutations and others that cause deletion or early 
truncation ofRUNX1, are frequently heterozygous, suggesting haploinsufficiency ofRUNX1 
expression is important in the pathogenesis of AML (Mikhail, eta! 2006). However, some 
mutations are homozygous, implying a gene dosage effect for the mutation (Silva, et a12003). 
AILL partial tandem duplications (PTD) occur in about 5% of AML and more in those 
with a normal karyotype or trisomy 11 (Basecke, et al 2006). They cause an in-frame repetition 
of a pair of fused exons e. g. exon 9 with exon 3 (e9/e3), but the functional abnormality is 
uncertain. MLL PTD retains the C terminus of the protein and there is evidence of lack of 
expression of the wild type MLL allele, in contrast to MLL translocations (Whitman, et al 2005). 
Therefore, it retains histone methyl transferase activity and can affect HOX gene expression, as 
demonstrated by the overexpression of HOXA genes in mouse models with MLL PTD 
(Dorrance, et a! 2006). MLL PTD at diagnosis confers a poor prognosis although this may be 
ameliorated by more intense chemotherapy (Whitman, et a! 2007a). 
Other genes involved in oncogenesis are also found mutated in AML. RAS encodes a 
GTPase and is an oncogene commonly mutated in cancer. It was originally found in bladder 
cancer as a homologue of a gene in murine sarcoma viruses (Parada, eta! 1982), and is involved 
in several cell-signalling pathways. Amongst the most important pathways it affects, are the 
mitogen-activated protein (MAP) kinase pathway involved in proliferation and the 
phosphoinositol-3 kinase (PI3K)/Akt pathway that promotes cell survival (Schubbert, et al 
2007). The mutations affect the GTPase activity of the protein, preventing its negative 
regulation by GTPase activating proteins. Mutations in the RAS pathway are found in a number 
of myeloid malignancies, especially juvenile myelomonocytic leukaemia (JMML) in which 
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mutations of RAS, NFl and PTPNII are frequent. Three isoforms of RAS have been identified, 
HRAS, KRAS and NRAS. Mutations of NRAS are found in approximately 10% of AML patients 
and KRAS mutations in 5% (Bacher, et al 2006, Bowen, et al 2005). 
RAS GTPases are downstream of several growth factor receptor kinases such as the 
granulocyte colony stimulating receptor and the erythropoietin receptor. FLT3 (fms-like 
tyrosine kinase 3) and c-KIT (cellular homolog of the feline sarcoma viral oncogene v-kit) 
receptors are type 3 receptor tyrosine kinases (RTKs) that can both be mutated in AML 
(Kitamura and Hirotab 2004, Parcells, et a! 2006). Type 3 RTKs are a family of transmembrane 
proteins involved in cell signalling; other members include platelet derived growth factor 
receptors alpha and beta, and CSFI-R. They have an extracellular domain that forms 
homodimers when its ligand attaches, and an intracellular tyrosine kinase that phosphorylates 
downstream targets including P13K and RAS. Both are involved with the proliferation of 
haematopoietic progenitors, when the appropriate cytokine attaches, FLT3 ligand to FLT3 
receptor or stem cell factor (SCF) to CKIT (Kitamura and Hirotab 2004, Wodnar-Filipowicz 
2003). Somatic mutations of FLT3 occur in about 25% of AML patients (Kottaridis, et al 2001, 
Thiede, et al 2002). The most common mutation is an internal tandem duplication (ITD) that 
affects the juxtamembrane region, leading to constitutive activation of the kinase (Griffith, et al 
2004). This activates the RAS signalling pathway, and explains why it is rare for RAS and FLT3 
mutations to coincide in the same patient (Bowen, et a! 2005). FLT3 ITT) mutations confer a 
poor prognosis, emphasising their importance in the pathogenesis of AML. Other mutations of 
FLT3 are found in AML, especially in the activation loop or tyrosine kinase domain (TKD). 
These also cause constitutive activation of the kinase, but their prognostic importance is 
controversial (Mead, et al 2007, Whitman, et a! 2007b). Mutations of KIT, which encodes the c- 
KIT receptor, are found in mast cell neoplasms (Kitamura and Hirotab 2004), and t(8; 21) and 
inv(16) AML. In the latter, they may confer a worse prognosis (Paschka, et a! 2006). Mutations 
occur in the activation loop of the receptor, at an analogous location to TKD mutations of FLT3. 
They also cause constitutive activation of the tyrosine kinase. 
CEBPA is a transcription factor gene important in the development of haematopoiesis. 
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It affects the differentiation of granulocytes and monocytes from multilineage precursors (Laslo, 
et al 2006), so that mice deficient in CEBPA have no neutrophils. Mutations of CEBPA occur in 
fewer than 10% of AML patients, and mostly affect those with a normal karyotype (Leroy, et al 
2005). The mutations are in two regions of the gene, at the carboxyl terminal affecting DNA 
binding, or at the amino terminal leading to a truncated 30 kD form (Snaddon, et a! 2003). The 
latter is a dominant negative mutation, so a heterozygous mutation is apparently sufficient for 
leukaemogenesis, but not infrequently both alleles are mutated. In patients with a familial 
CEBPA mutation, the heterozygous mutation is inherited in an autosomal dominant fashion, but 
a second somatic CEBPA mutation is acquired at diagnosis of AML, leading to a biallelic 
mutation (Smith, et a! 2004b). 
More recently, a mutation of NPM1 (nucleophosmin) has been found to be prevalent in 
normal karyotype AML (Falini, et al 2005). NPM1 is a fusion partner in several other 
haematological malignancies, including PML/NPM found in rare forms of APML, and 
NPM/ALK in anaplastic large cell lymphoma. It is a transcription factor involved in the nuclear- 
cytoplasmic shuttling of proteins and nucleic acids (Grisendi, et al 2006). Mutation of exon 12 
leads to cytoplasmic rather than nuclear expression in AML cells because of defects in its 
shuttling ability. The heterozygous mutation has a dominant negative effect because it forms 
heterodimers with the wild type protein. At least one of the effects of the mutation is to 
delocalise ARF (also known as p21), a growth inhibitor. In the absence of FLT3 ITD mutations, 
NPM1 mutations confer a relatively good prognosis in patients with normal karyotype AML 
(Falini, et al 2005). 
Small studies into WTI have demonstrated mutations in about 10% of AML patients 
(King-Underwood, et al 1996, Summers, et al 2007), moreover there is an association with 
refractory disease. WTI was originally described as a TSG associated with Wilm tumours, but 
was soon discovered to be critical for renal development because inherited mutations lead to 
renal disease including Denys-Drash syndrome (Wagner, et al 2003). Although it encodes a 
transcription factor with a zinc finger region, it has many isoforms due to alternate splicing and 
is expressed in so many tissues that it is unclear how it functions. A recent paper has reported 
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51 mutations in 470 AML samples from the MRC AML10 and 12 studies, confirming the 
results of the smaller studies, and has found most of the mutations affect the C terminal DNA 
binding domain (Virappane, et al 2008). 
As for all cancers, multiple mutations are required for development of the malignancy 
(Kinzler and Vogelstein 2002). Translocations only lead to AML in transgenic mouse models 
after several months, presumably after further mutations have taken place (Cuenco, et al 2000). 
Other mutations, such as FLT3 ITD, only led to a myeloproliferative disease rather than AML 
in mouse models (Lee, et a! 2005). The familial leukaemias such as familial CEBPA mutations 
and FPD/AML show long latencies before AML is apparent, consistent with the multi-step 
theory of cancer or leukaemia development. 
Some mutations have a tendency to occur together, such as NPMI and FLT3 ITD 
(Falini, et al 2005), and inv(16) or t(8; 21) and C-KIT (Paschka, et al 2006). Other mutations are 
mutually exclusive such as RAS and FLT3, presumably because they act along the same 
pathway (Bowen, et a! 2005). It has been proposed that there are two types of mutation, referred 
to as class I (proliferative) and class II (impairing differentiation), which are both required to 
cause AML (Kelly and Gilliland 2002). Examples of class I mutations would be FLT3, CKIT 
or RAS. Examples of class 2 mutations would be translocations such as t(8; 21) or mutations 
such as CEBPA. 
Although haematopoietic cells are thought to have fewer mutations than solid tumours, 
it is still likely there are several genetic events, be they other mutations, epigenetic or in non- 
coding regions that may contribute to the leukaemia, or at least alter the phenotype. Therefore, 
this theory is likely to be a simplification of the pathogenesis of AML. In addition, the function 
of many of these genes is more complex than simply preventing differentiation or being 
proliferative. For example, NPM protein has anti-apoptotic and proliferative effects as well as 
preventing differentiation (Grisendi, et al 2006). 
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1.8 Therapy of AML 
Despite an increased understanding of the biology of AML in the last 20 years, the 
therapeutics of AML has changed relatively little in that time. Most patients with AML are in 
an elderly age group and their prognosis from this risk factor alone would dictate that they 
should be treated supportively rather than with curative intent. Other patients may have co- 
morbidities e. g. ischaemic heart disease, that weigh against the benefits of intensive 
chemotherapy. Supportive care includes blood product support, antibiotics when infections arise 
and some degree of myelosuppressive therapy, if the patient is symptomatic from a rising 
leukaemic blast count. Appropriate myelosuppresssive drugs include 6-mercaptopurine (6-MP), 
low dose cytarabine arabinoside (araC) or hydroxyurea. In a large prospective randomised trial 
between low dose araC and hydroxyurea for elderly AML (MRC AML14), low dose araC had 
an improved overall survival (OS) (odds ratio 0.6; 95% confidence interval, 0.44-0.81; 
P 0.0009), although there was only a 13% OS for all patients at 1 year (Burnett, et a! 2007). 
In higher doses 6-MP and araC are used with curative intent. After the Second World 
War, thiopurines such as 6-MP were amongst the first cytotoxic agents in development to have 
an effect on AML (Burchenal, et a! 1953, Scott 1957). By the 1960s the purine analogue, araC, 
and anthracycline, daunorubicin, were used as single agent therapy for AML, and could produce 
a small number of morphological complete remissions (CR) (Malpas and Scott 1968). Their 
combined use led to 60-65% of patients going into CR (Crowther, eta! 1970, Yates, et al 1973). 
The protocol of Yates et al, DA 3+7 (three daily doses of daunorubicin, and 7 days of araC) has 
become the template for the modern standard of induction chemotherapy. 
The most important chemotherapeutic agents continue to be anthracyclines and 
cytarabine arabinoside. The initial induction course of chemotherapy causes myelosuppresion 
for 20 to 30 days, with the aim of producing CR. This can be achieved in adults under the age of 
50-55 in 73-85% of patients (Grimwade, et al 1998, Rohatiner, et al 2000), but this falls to 55- 
60% in those over 60 years of age (Grimwade, et a! 2001, Milligan, et al 2006). 
Remission is consolidated with further courses of chemotherapy, e. g. high dose araC, or 
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it may involve high dose chemotherapy (HDT) with autologous stem cell support. Debate 
surrounds the dose of araC required, although a higher dose is associated with a prolonged 
survival (Bradstock, et al 2005, Mayer, et al 1994). Trials at Barts using historical controls 
show an improvement in recurrence free survival (RFS) for HDT (hazard ratio 0.5 P=0.005) but 
no significant improvement in OS in comparison with historical controls having chemotherapy 
alone (Rohatiner, et al 2000). The national prospective randomised trial, MRC AML10, gave 
similar results for HDT, with an improvement in RFS (54% v 40%, P=0.04) but not in OS 
(Burnett, et a! 1998). In patients at high risk of relapse, consolidation with allogeneic stem cell 
transplantation, providing a graft versus leukaemia effect, may be considered. However, the 
high treatment related mortality (TRM) may negate the improved RFS. In recent years, four 
large prospective trials have reported the results of randomisations between those patients who 
have an available related matched donor for allogeneic transplant and those without (Burnett, et 
al 2002, Cornelissen, et a12007, Jourdan, et al 2005, Suciu, et al 2003). In MRC AMLIO there 
was no significant improvement in OS for those autografted against those without an allogeneic 
donor (56% versus 50% at 7 years, P=0.01), although there may be an advantage in OS for 
intermediate risk patients (Burnett, et al 2002). A meta-analysis of these four trials for OS 
demonstrated a benefit for those with a donor, especially for those with intermediate and poor 
risk cytogenetics, and for those below the age of 40 years (Cornelissen, et al 2007). These 
results imply that good risk patients should be treated with chemotherapy rather than HDT, but 
there is a place for allogeneic transplantation for intermediate and poor risk patients. Trials are 
currently underway using reduced intensity instead of ablative conditioning for allogeneic 
transplant, as this may be benefit older patients for whom the TRM of ablative conditioning is 
too high (Davies, et al 2006, Mohty, et al 2005). These trials have already shown a long-term 
benefit for some patients. 
Consolidation is designed to reduce the disease load, because although these patients 
are in morphological and clinical remission after induction, leukaemia cells are still present. The 
minimum levels of discrimination of minimal residual disease by morphology or fluorescent in 
situ hybridisation (FISH) is approximately 1 in 100 cells; by immunophenotyping it is 1 in 103- 
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104 cells (van Dongen, et al 2005), and the best discrimination by polymerase chain reaction 
(PCR) is about 1 in 104-105 (Grimwade 2002). Therefore, even below an undetectable level, 
leukaemic cells are present. One of the aims of new treatments has been to improve 
consolidation therapy to prevent relapse from the residual leukaemia. 
Novel targeted therapies are now being used based on the biological understanding of 
AML. ATRA used in conjunction with chemotherapy has improved the outcome of APML 
(Tallman, et a! 1997) (although the discovery of ATRA preceded our understanding of the 
biology of APML). Other targeted therapies are in clinical trials. Gemtuzumab ozogamicin is a 
conjugate of an antibody against CD33 and a cytotoxic antibiotic. It has produced CRs in some 
patients in phase 2 trials (Sievers, et a! 2001), and is now in phase 3 trials, including the UK 
national AML trial for patients below the age of 60 years, AML 15. The FLT3 receptor inhibitor, 
CEP701, has also been used in AML15, because it has shown clinical responses in phase 2 trials 
(Knapper, et a! 2006, Smith, et a! 2004a). 
Although there is reason to hope that these new treatments may improve the outcome of 
AML, it is new biological targets may only come about from an improved understanding of the 
biology of AML. One of the most significant steps forward in this understanding has come from 
the use of microarray technologies. 
1.9 Genomics and the study of AML 
The Human Genome Project (HGP) has allowed detailed annotation of the whole of the 
human genome allowing a huge amount of data to be mined (International Human Genome 
Sequencing Consortium 2001). Several large-scale projects have subsequently been developed 
from the HGP, including the Cancer Genome Project (Greenman, et al 2007), the HapMap 
(International HapMap Consortium 2005) and more recently and more recently a project 
advanced by the Human Genome Structural Variation Working Group (Human Genome 
Structural Variation Working Group 2007). 
Technological advances have been at least part of the reason these advances have been 
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possible. These technologies have also been put to use in providing high-throughput techniques 
that can analyse many parts of the genome on a single sample. Microarrays were the first 
example of this, initially spotting hundreds or thousands of unique nucleotide sequences at a 
time, to which a DNA or RNA sample could be hybridised (Ramsay 1998). The signal 
amplitude produced by each spot represents the quantity of each unique sequence in the sample. 
Others have developed technologies to increase the number of nucleotides that can be analysed 
on a slide or chip, e. g. Affymetrix uses photolithography, and Illumina uses micro bead 
technologies. 
Many of the initial uses of microarrays were in acute leukaemia, analysing the 
transcriptome, in other words mRNA expression (Golub, et al 1999). Further developments 
have seen their use in analysing DNA copy number using the arrays as an alternative to 
comparative genetic hybridisation (CGH), the technology being called array CGH (Wicker, et al 
2007). Microarrays have also been developed to show homozygosity or heterozygosity for the 
alleles of single nucleotide polymorphisms (SNPs) (Affymetrix 2003). These SNP arrays have 
become useful to find regions of loss of heterozygosity in cancer. 
1.9.1 Gene expression profiling 
The level of expression of mRNA of individual genes reflects the phenotype of the 
leukaemic cell, as it is the translated genes that are involved in the functions of the cell. Several 
genes have been described that were highly expressed in AML cells, e. g. WTI (Inoue, et al 
1994), EVI1 (Barjesteh van Waalwijk van Doorn-Khosrovani, et al 2003), BAALC (Tanner, et 
al 2001) and MNl (Heuser, et a! 2006). WTI was originally found mutated in association with 
Wilm's tumours, and was subsequently found to be over expressed in neuroectodermal and 
some haematological malignancies. Evil is involved in translocations of chromosome 3q in 
AML and MDS, and was subsequently found to be over expressed in AML. BAALC is on the 
long arm of chromosome 8, and was found over expressed in some AML patients with trisomy 
8 using representational difference analysis, comparing them with AML patients with a normal 
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karyotype (Tanner, et al 2001). MNI is involved in a rare t(12; 22) translocation in AML 
(Heuser, et a! 2006). 
While the function of these genes is currently being investigated, clinical studies have 
shown high expression of these genes is associated with a poor outcome. A high WTI 
expression was associated with a3 year OS of 13% versus 38% (P=0.038) in 129 patients 
(Bergmann, et al 1997) in one study, although another could find no association in 125 patients 
(Schmid, et al 1997). High expression of WTI is currently being investigated as a marker for 
minimal residual disease after chemotherapy in the UK national clinical trial, AML15. In a 
study of 309 patients, those with high BAALC expression under the age of 60 years had a3 year 
OS of 36% v 54% (P = . 00 1) (Baldus, et a! 
2006). High EVIL expression was associated with 
poor risk cytogenetics, but also predicted a poor OS in patients with intermediate risk 
cytogenetics (P=0.05), although patient numbers were small (Barjesteh van Waalwijk van 
Doorn-Khosrovani, et a! 2003). High MNI expression predicted a poor OS in 142 patients with 
AML (38.1% versus 5 8.8% at 3 years, P= . 03) 
(Heuser, et al 2006). 
If single gene expression can give prognostic information in AML, then the expression 
of many genes may be able to improve the classification of AML. Expression arrays measure 
the mRNA expression of thousands of genes across the genome simultaneously. Initial studies 
demonstrated it was possible to differentiate AML from ALL (Golub, et al 1999), and 
subsequently patterns have been found that can distinguish AML phenotypes and cytogenetic 
subtypes (Debemardi, et al 2003). Because many of these subgroups have prognostic 
importance, the next step was to show that expression patterns can correlate with current 
prognostic subgroups and define new prognostic groups (Valk, et al 2004). This is leading to 
international collaborations to use expression profiles as a diagnostic tool in AML and other 
haematological malignancies in the MILE study (Mills 2005). 
Whilst molecular classification has been very successful, finding the biological 
importance of expression profiles has been more difficult. Although the level of mRNA 
expression does not necessarily correlate with protein expression, for the genes important in 
AML their correlation seems to be good (Kern, et a! 2003). A few genes have been identified 
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from genome wide expression studies, including MN1, which was highly expressed in the 
profiles of patients with a poor response to chemotherapy (Heuser, et al 2006). There are 
several complications in discovering individually important genes from expression profiling. 
The number of genes in an array means to make statistically significant correlations requires 
large numbers of samples. Influences on the level of expression of many genes are 
multifactorial, leading to variability in their expression. There are also factors independent of 
the leukaemia that may affect expression profiles e. g. delayed sample collection leading to 
increased leukaemic cell apoptosis. From a biological point of view, mRNA expression takes no 
account of different splice variants, e. g. the expression of exon 9a from RUNX1 TI in AML with 
t(8; 21) has been shown to be leukaemogenic (Yan, et a! 2006). Expression of mRNA also does 
not reveal the effects of post-translational protein modifications e. g. glycosylation. 
Despite these problems, there are robust patterns of expression that suggest groups of 
genes that are involved in leukaemogenesis. AML patients with translocations involving MLL 
have an increased expression of some HOX A and B genes, in a similar pattern to some patients 
with normal karyotype AML (Debernardi, et al 2003). These patients also seem to be associated 
with NPM1 mutations (Alcalay, et a! 2005). As well as patterns, expression of individual genes 
is leading to an understanding of some of the downstream effects of mutations. Increased 
CXCR4 expression is seen in a subset of patients that includes those with FLT3 ITD mutations, 
and confers a poor prognosis (Rombouts, et al 2004). The homeobox gene, CDX2 has been 
found to be highly expressed in almost all AML patients, and can produce a transplantable 
AML mouse model, suggesting that this is part of a common pathway in AML (Scholl, et al 
2007). 
In addition to the deregulation of expressed genes, the effect of non-coding RNA 
transcripts on the leukaemia phenotype has been described. MicroRNAs are short hairpin 
shaped oligonucleotides that prevent the translation of specific mRNAs (Calin and Croce 2006). 
They are coded in intergenic and intronic regions as long precursor forms of about 60-100 
nucleotides, before being spliced into their active short form of about 20-22 nucleotides. One 
microRNA, mir-181 a has been associated with acute monocytic and myelomonocytic leukaemia 
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(Debemardi, et al 2007). As most of the genome is untranslated there are likely to be many 
more non-coding regions that are important in leukaemogenesis. 
1.9.2 DNA arrays 
CGH uses a comparison of pooled normal DNA to tumour DNA hybridised to normal 
chromosomes to see gains and deletions (Kallioniemi, et al 1994). Its advantage compared to 
conventional cytogenetic analysis is the ability to discriminate relatively small changes that may 
be missed when looking at chromosomal bands. Array CGH (aCGH) is an even higher 
resolution version of this process (Strefford, et a! 2006). In this case, the comparison is made on 
hybridisation to thousands of spotted probes across the genome on a microarray slide. The 
probes are usually bacterial artificial clones (BACs) that are from 1Mb to a few thousand bases 
in size, considerably smaller than a chromosome band. More recently, the resolution has 
increased so that tiling arrays for individual chromosomes are using oligonucleotide probes 
(Wicker, et al 2007). It has been used predominantly in solid tumours where metaphase 
cytogenetic analysis is much more difficult. A recent study using relatively low resolution 
aCGH has identified recurrent regions of gain and deletion in complex karyotype AML 
(Rucker, et al 2006). CDX2 was discovered as a potential important gene in AML from its 
amplification on chromosome 13 by aCGH (Scholl, et al 2007). 
1.10 SNP array technologies 
Single nucleotide polymorphisms (SNPs) are the commonest genetic variation in the 
human genome, occurring about every 200bp (Sachidanandam, et a! 2001). They are mostly 
biallelic so the two alleles may form transitions between purines i. e. adenine and guanine, or 
pyrimidines i. e. thymine and cytosine. Alternatively, transversions can occur between purine 
and pyrimidines. They are located throughout the genome, although they are more frequent in 
GC rich regions (Sachidanandam, et al 2001); this may be due to nucleotide excision repair 
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correcting methylated cytosines (CpG motifs), which can be converted to thymine. 
Most SNPs are in intergenic regions and whilst they are useful markers (see association 
studies below), they are unlikely to have effects on cellular function. However, SNPs in gene 
promoter regions have the potential to alter the expression of their associated gene, and SNPs 
within exons alter the coding of the gene itself. SNPs in exons can be synonymous, altering the 
codon but not the amino acid, or non-synonymous, altering the amino acid structure of the gene 
and producing a polymorphic protein. In pharmacogenetics, non-synonymous polymorphisms 
are responsible for variation in the function of drug-metabolising enzymes (Ahmadi, et al 2005, 
Marsh and McLeod 2004). Recently, even synonymous SNPs have been shown to alter the 
function of proteins, e. g. synonymous MDRJ variants have altered ability to pump fluorescent 
substrates out of cells (Kimchi-Sarfaty, et a! 2007). Synonymous codons are not used equally in 
the genome, and it is hypothesised that alternate tRNA molecules complementary to these 
codons may alter protein folding. 
1.10.1 Association studies 
The database for SNPs is maintained in an open access repository known as dbSNP 
(National Center for Biotechnology Information 2007). There are currently over 11.75 million 
SNPs documented in the database from build 128. Each SNP is recorded with data about its 
flanking sequence, its genomic location and population frequency of each allele where 
available. 
The HapMap Project (International HapMap Consortium 2005) has produced a database 
of the distribution of SNPs in various populations and the way in which linkage disequilibrium 
causes them to be inherited as haplotypes blocks. Various ethnic groups have inherited different 
haplotypes, because of the migration patterns of peoples since the original evolution of Homo 
sapiens. The HapMap Project has analysed African (Yoruban, from West Africa), Caucasian 
(Americans of northern European ancestry), and east Asian (Japanese and Chinese) individuals. 
One of the main aims of the genome-wide approach to genotyping has been to look for inherited 
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haplotypes that may be associated with diseases that have polygenic inheritance, e. g. non- 
insulin dependent diabetes mellitus. High-throughput techniques using microarrays are now 
able to look at several thousand SNP allelotypes at once (Lindblad-Toh, et a! 2000), and have 
been used to identify novel loci associated with disease, e. g. in breast cancer (Easton, et al 
2007) and prostate cancer (Gudmundsson, et al 2007, Yeager, et a! 2007). These studies require 
large populations of patients with disease and controls, because of the statistical significance 
required with such large numbers of SNPs, and critically they require repetition in other 
populations to reduce the risk of false positives. 
The haplotype approach means the number of SNPs in these arrays can be reduced 
when performing association studies, as many SNPs in the same haplotype block will be in 
linkage. Therefore, single tagging SNPs can be used to represent a whole haplotype. For 
example, tagging SNPs have been used to produce a set of SNPs to represent variation in drug 
metabolism enzymes and other genes that affect pharmacokinetics (Ahmadi, et a! 2005). 
Another use for high-resolution SNP arrays is for linkage analysis, to identify genes in 
families with rare inherited disorders. The rare autosomal recessive disease harlequin 
ichthyosis, a fatal skin disease, is such an example. Linkage analysis and a common region of 
homozygosity identified a mutation in ABCA12 at chromosome 2q35 (Kelsell, eta! 2005). 
1.10.2 Cancer studies 
The identification of somatically acquired regions of homozygosity i. e. loss of 
heterozygosity (LOH), is important in cancer. Regions of LOH have been assumed to contain 
TSGs, which would be mutated and then undergo gene conversion, as is consistent with 
Knudson's two hit hypothesis (Knudson 1971). Most genetic abnormalities in cancer are 
somatically acquired, involving amplifications, deletions or smaller single gene mutations. SNP 
arrays can be analysed to look for LOH in the tumour compared to germline DNA. Prior to this 
technology, LOH was identified by the PCR of microsatellite markers, which consist of short 
tandem repeats polymorphic in their length. There are far fewer microsatellites compared with 
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SNPs, limiting their resolution and genome coverage. 
An additional advantage of SNP arrays is to give a measure of DNA copy number. 
Calling a SNP homozygous or heterozygous requires a quantitative assessment of one allele 
against the other. The signal values used can also measure the total quantity of DNA in a similar 
manner to aCGH (Huang, et a! 2004). Therefore, SNP arrays have an advantage over aCGH, in 
simultaneously identifying deletions and LOH. 
Complicating the detection of somatically acquired gains and deletions is the 
recognition of structural polymorphisms in the human genome i. e. insertion-deletions (indels) 
(Conrad, et a12006) and copy number variants (CNVs) (Sebat, et a! 2004). The median size of 
these variants is 228kb and they are distributed across the genome, affecting many transcribed 
genes (Redon, et a! 2006). There is at least one report associating a copy number polymorphism 
with disease, in a type of glomerulonephritis (Aitman, et at 2006). Many of these discoveries 
have been made using high-resolution SNP arrays, which emphasises the need to eliminate 
germ line variants when searching for somatic aberrations. 
Initial studies used arrays with approximately 1500 SNPs to identify LOH in small cell 
lung cancer, using paired normal lung tissue as a control, and CGH to confirm these as deletions 
(Lindblad-Toh, et a! 2000). Subsequently, copy number was also analysed with LOH in cancer 
cell lines with paired B lymphoblastoid cell lines (Zhao, et a! 2004). This study described 35 
amplifications and deletions, as well as two cases of copy number neutral LOH in chromosome 
9 and 13, each confirmed by real time PCR. This was the first description of acquired 
uniparental disomy (UPD) using a SNP array. Analyses of other tumours including bladder 
(Hoque, et a! 2003), lung (Janne, et a! 2004) and breast (Schubert, et al 2002) similarly 
demonstrate the highly disordered nature of chromosomes in epithelial solid tumours. 
Data from the Mitelman Database of Chromosomal Aberrations in Cancer (National 
Cancer Institute 2006) confirm that solid tumours often have a much more disordered karyotype 
than leukaemias (Mitelman, et a! 2004). Unlike most cases of solid tumours, leukaemias usually 
have conventional cytogenetic analysis performed at diagnosis, allowing a comparison with 
array based chromosomal analysis including SNP arrays. Both of these factors give an 
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advantage to analysing AML by SNP arrays. Firstly, confirmation of the karyotype by SNP 
array demonstrates the validity of using this platform (Chapter 3 ). Secondly, abnormalities 
detected by SNP arrays that are cryptic to karyotype analysis can identify mechanisms of 
disease pathogenesis. This is particularly important when 40% of AML have no karyotypic 
abnormality. Analysis of paediatric precursor B cell ALL with arrays of 500,000 SNPs have 
identified microdeletions of less than 1Mb that contain genes involved in B cell development, 
e. g. PAX5 (Mullighan, et a! 2007). In AML, acquired UPD has been discovered in 15-20% of 
cases (Gorletta, et al 2005, Raghavan, et al 2005), and the region of LOH in many cases 
contains homozygous mutated genes involved in the pathogenesis of AML, e. g. CEBPA 
(Fitzgibbon, et al 2005) (Chapter 4 ). The application of SNP arrays in haematological 
malignancy to identify novel genetic aberrations has now been made in myeloma (Walker, et al 
2006), follicular lymphoma (recurrent UPD of 6p) (Fitzgibbon, et al 2007) and juvenile 
myelomonocytic leukaemia (UPD of 17q resulting in a homozygous NF1 mutation) (Flotho, et 
al 2007, Stephens, et a! 2006). Additionally, acquired UPD has been discovered recurrently in 
epithelial tumours e. g. basal cell carcinomas have UPD 9q with the region of LOH containing a 
homozygously mutated PTCH gene (Teh, et al 2005). The following chapters outline the 
development of the use of SNP arrays to analyse AML for regions of LOH and DNA copy 
number, the discovery of acquired UPD as a recurrent genetic aberration in AML, and the 
consequences of UPD for the pathogenesis and subsequent progression of the disease. 
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Chapter 2 
Materials and Methods 
2.1 Ethics approval 
Approval had previously been obtained for the collection and cryopreservation of 
leukaemia samples, blood and bone marrow (study P/02/067 approved by East London and City 
Local Research Ethics Committee). Excess samples were obtained with consent for storage as 
part of the clinical management of the patients. Samples were stored in the Medical Oncology 
Tissue Bank, Barts and the London School of Medicine and Dentistry Human Tissue Resource 
Centre (Human Tissue Authority deemed license 12199). For this study, ethical approval was 
obtained for SNP genotyping of the blood and marrow samples and genotyping germ line 
material from remission samples (study P1/03/310 approved by East London and City Local 
Research Ethics Committee). 
2.2 Cryopreservation of leucocytes 
AML bone marrow and blood samples were previously taken from patients at diagnosis 
and at subsequent times during the course of their disease. Some samples were obtained by 
leucopheresis. 
Leucocytes were Ficoll separated and cryopreserved in liquid nitrogen. In detail, an 
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equal volume of RPMI-1640 medium (Moore, et al 1967) was added to the leucocyte sample (in 
ACDA, acid citrate dextrose solution, or EDTA, ethylene diamine tetra-acetic acid). The sample 
was divided into 10m1 aliquots and added carefully to 5 mis of Lymphoprep (AXIS-SHIELD 
PoC AS Norway) (Sodium Diatrizoate 9.1% (w/v) Polysaccharide 5.7% (w/v)) as to maintain 
the layers. It was centrifuged at 1500 rpm for 25 mins with no brake. The buffy coat was taken 
off into 10mis RPMI and centrifuged at 1300 rpm for 10 mins. The supernatant was discarded 
and the pellet resuspended in RPMI in a cryovial. Freeze mix was added drop wise. The vial 
was stored in liquid nitrogen. 
23 DNA extraction 
Genomic DNA was extracted using standard phenol-chloroform methods. In detail, the 
samples retrieved from cryopreservation were incubated for 1-2 mins at 37°C. The suspension 
of cells was taken into a2 ml tube and centrifuged at 13,000 rpm in a bench centrifuge 
(Eppendorf 5417R) for 5 mins at 4°C. The supernatant was removed and the pellet of cells 
resuspended in 1-2 ml (or more) of digestion buffer (100 mM NaCl, 10 mM Tris HCl pH 8,25 
mM EDTA pH 8,0.5% SDS) depending on the size of the pellet. If necessary, the suspension 
was transferred to a 15 ml falcon tube. 50-100 gl of proteinase K (in a buffer of 50 mM Tris pH 
8 and 1.5 mM Ca acetate and kept on ice) was added to make about 0.1 mg/ml. The mixture was 
vortexed and incubated in a water bath at 56°C for 12-18 hours overnight. 
The digested cells had an equal volume of phenol (ultrapure, equilibrated pH8.0) (USB 
Corporation, Cleveland, OH, USA) added to them. The mixture was shaken and centrifuged for 
10 mins (3000 rpm for falcon tubes, 10,000 rpm for bench centrifuge). The upper aqueous layer 
containing DNA was removed and put into a fresh tube and the remaining organic layer 
containing protein discarded. An equal volume of chloroform and phenol (each 50% by volume) 
was added and the solution mixed and spun as before. Again, the aqueous layer was put in a 
fresh tube avoiding the cloudy interface. If the solution was still cloudy, a further wash with 
phenol-chloroform was performed; otherwise, an equal volume of chloroform only was added. 
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The solution was mixed and spun as before and once more the aqueous layer taken into a 15 ml 
falcon tube. One-tenth-volume Sodium citrate 0.3 M and twice the volume of 100% ethanol was 
added. The solution was gently agitated to allow the strands of DNA to precipitate and coalesce. 
The DNA was removed with a sterile inoculation loop and washed with a few drops of 75% 
ethanol. After drying a little in air, the DNA was placed in an appropriate volume of reduced 
EDTA TE buffer (0.1 mM EDTA, 10 mM Tris HCI, pH 8.0). EDTA can inhibit some of the 
enzymic reactions in the GeneChip mapping array protocol, hence the lower concentration of 
EDTA. The DNA was allowed to dissolve overnight at 4°C. The concentration of DNA and 
quality was measured by a spectrophotometer (ND-1000, Nanodrop, Wilmington, DE, USA), as 
expressed by 260 nm/280 nm and 230 nm/260 nm ratios. Ideally, the 260/280 ratio would be 1.8 
showing the least protein contamination, and the 230/260 ratio greater than 2 showing the least 
organic solvent contamination. 
2.3.1 DNA extraction from organic fraction after RNA isolation using Trizol reagent 
Samples that had previously had RNA extracted using the Trizol reagent (Invitrogen) 
had the organic fraction stored at -20 to -70°C. The sample was retrieved from the freezer and 
allowed to defrost at room temperature (RT). The vial was centrifuged at 2000 g for 15 mins at 
4°C and any remaining aqueous top layer removed. Ethanol 100% was added at 0.3 ml/ml of 
the original volume of Trizol added. The solution was mixed and allowed to stand at RT for 3 
mins before centrifuging at 2000 g for 5 mins at 4°C. A small pellet remained and the pink 
phenol-ethanol solution containing protein was removed carefully, and stored at -20°C. Sodium 
citrate 0.1 M in 10% ethanol was added at 1 ml/ml of Trizol. The solution was mixed and 
allowed to stand at RT for 30 mins before being spun as before. Again, the supernatant was 
removed (and discarded) leaving the pellet. The pellet was washed once more with sodium 
citrate and ethanol as above. Ethanol 75% at 2 ml was then added, and the solution mixed and 
allowed to stand for 20 mins at RT. After centrifuging again as above, the ethanol was carefully 
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removed and the pellet allowed to dry in air for 10 mins. The DNA was dissolved in 20-100 µg 
of reduced EDTA TE buffer overnight at 4°C and the concentration measured as above. 
2.4 GeneChip array assay (Matsuzaki, et al 2004) 
2.4.1 Preparation of reduced complexity samples 
For each individual assayed, 250 ng of genomic DNA was digested with 10 U of Xba I 
(New England BioLabs). It was made up to 20 µL with 2 µl of IOx NEBuffer 2 (New England 
Biolabs) (NEBuffer 2 contains 500 mM NaCl, 100 mM Tris-HCI, 100 mM MgCl2 and 
10 mM dithiothreitol pH7.9 at 25°C), 2 id IOx bovine serum albumin and molecular biology 
grade water. The mixture was prepared on ice in a pre-PCR designated laminar airflow hood to 
prevent contamination with DNA template, and DNA added in a PCR staging hood. The 
mixture was incubated for 2h at 37°C. Following heat inactivation at 70°C for 20 min, 0.25 gM 
of adaptor (5'phosphate-CTAGAGATCAGGCGTCTGTCGTGCTCATAA-3', and 5'- 
ATTATGAGCACGACAGACGCCTGATCT-3' synthesised by QIAGEN) was ligated to the 
digested DNA with T4 DNA Ligase (New England BioLabs) in 25 µL for 2h at 16°C. The 
ligation reaction was stopped by heating to 70°C for 20 min, and then diluted fourfold with 
water. For each sample, four PCRs were run using 10 µL of the diluted ligation reaction (25 ng 
of starting DNA) in 100 µL volumes containing 0.75 µM of primer (5'phosphate- 
CTAGAGATCAGGCGTCTGTCGTGCTCATAA-3'), 0.25 mM dNTPs, 2.5 mM MgC12,10 U 
AmpliTaq Gold (Applied Biosystems), and PCR Buffer (Applied Biosystems). Thirty-five 
cycles of PCRs were done in a MJ DNA Engine Tetrad Cycler (MJ Research). The cycling 
program was 95°C denaturation for 20 sec, 59°C annealing for 15 sec, and 72°C extension for 
15 sec. As a check, 3 pL of PCR products were visualized on 2% TBE agarose gels to confirm 
the size range of amplicons. However, it was soon clear that if sufficient quantity of DNA was 
obtained after purification, then this check was unnecessary. 
47 
Chapter 2 
The PCR products were purified using QlAquick spin columns (QIAGEN). 500 µl of 
Buffer PB was added to each 100 µl PCR sample, which was applied to the column set in a 
collection tube. The column was centrifuged at 13000 rpm at RT (the speed and temperature of 
all centrifugations for the QIA quick protocol) for I min and the flow through discarded. 750 gl 
of buffer PE was added to the column and centrifuged as before, discarding the flow through 
again. The column was centrifuged an additional 5 mins. The column was placed in a fresh 
1.5m1 tube and 55 gl of Buffer EB was applied to the centre of the membrane of the column. 
The column was incubated at room temperature for 5 mins and centrifuged for 2 mins. The 
eluate was then applied to the second column and allowed to stand as before for 5 mins before 
centrifugation for 2 mins again. This was repeated until the PCR products from all 4 columns 
were eluted. This protocol was found to be slow and inefficient at obtaining sufficient purified 
PCR product. Therefore, a new protocol was devised using Ultrafree-MC, PLTK Ultracel-PL 
Membrane, 30 kDa columns (Millipore, Billerica, MA). PCR products from the four reactions 
were combined and applied to the column and centrifuged for 15 mins at 2000 g at RT. The 
flow through was discarded, 250 id of Ultrapure water was added and the tube centrifuged for 
10 mins more. If more than 5 µl of liquid remained in the column, then the tube was centrifuged 
for 1 or 2 mins more until it reduced. 30 µl of EB buffer was applied to the membrane and 
allowed to stand for 1 min before being taken off into a clean 1.5m1 tube. 
PCR yields, based on absorbance readings at 260 rim, were typically 15-20 µg. If the 
yield was less than 12µg, it was found that the call rate subsequently obtained would be low 
(<85%), so one would not proceed with that sample. To allow efficient hybridization to the 25- 
mer oligonucleotides on the array, PCR amplicons were fragmented with DNAse I (Amersham 
Biosciences). Here, 0.24 U of DNAse I was added to 20 µg of purified PCR amplicons in a 55 
µL volume containing 50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium 
acetate, and 1 mM dithiothreitol for 30 min at 37°C, followed by heat inactivation at 95°C for 
15 min. Fragmentation products were visualized on 2% TBE agarose gels. Occasionally, 
fragmentation would be inadequate and so the fragmentation was repeated, but this time only 
incubating for 5 mins before inactivation. The 3' ends of the fragmented amplicons were 
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biotinylated by adding 143 µM of a proprietary DNA labelling reagent (Affymetrix) using 
Terminal Deoxynucleotidyl Transferase (Promega) in a 70 µL volume containing 100 mM 
cacodylic acid (pH 6.8), 0.1 mM dithiothreitol, and 1 mM CoC12 for 2h at 37°C, followed by 
heat inactivation at 95°C for 15 min. 
2.4.2 Genotyping by Allele-Specific Hybridization 
The fragmented and biotinylated PCR amplicons were combined with 11.5 µg/ml 
human Cot-i (Invitrogen) and 115 pg/ml herring sperm (Promega) DNAs. The DNAs were 
added to a hybridization solution containing 2.69 M tetramethylamonium chloride (TMACI), 56 
mM MES, 5% DMSO, 2.5 X Denhardt's solution, and 0.0115% Tween-20 in a final volume of 
260 µL. The hybridization solution was heated to 95°C for 10 min, then placed on ice. Next, 
200 µL of the hybridization solution was injected into cartridges housing the oligonucleotide 
arrays (Affymetrix GeneChip IOK Mapping Array version Xba131 or Xba142). Hybridization 
was carried out at 48°C for 16-18 h in a rotisserie rotating at 60 rpm. Following the overnight 
hybridization, the arrays were washed with 6X SSPE and 0.01% Tween-20 at 25°C, then more 
stringently washed with 0.6X SSPE and 0.01% Tween-20 at 45°C. Hybridization signals were 
generated in a three-step signal amplification process: 10 µg/ml streptavidin (Pierce) was added 
to the biotinylated targets hybridized to the oligonucleotide probes, and washed with 6X SSPE 
and 0.01% Tween-20 at 25°C, followed by the addition of 5 pg/ml biotinylated goat anti- 
streptavidin (Vector) to increase the effective number of biotin molecules on the target; finally, 
streptavidin R-phycoerythrin (SAPE) conjugate (Molecular Probes) was added and washed 
extensively with 6X SSPE and 0.01% Tween-20 at 30°C. The Streptavidin, Antibody, and 
SAPE were added to arrays in 6X SSPE, 1X Denhardt's solution, and 0.01% Tween-20 at 25°C 
for 10 min. The washing and staining procedures were performed using Affymetrix fluidics 
stations. Arrays were scanned using the GeneArray (Agilent) or GCS3000 (Affymetrix) 
scanners. Scan images were processed to get hybridization signal intensity values using either 
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Micro Array Suite (MAS) v5 software (Affymetrix) or GCOS vl software (Affymetrix). The 
genotype-calling algorithm as previously described (Liu, et al 2003) was implemented in 
GenoTyping Tools (GTT; Affymetrix) and GDAS v2 (Affymetrix) analysis software. Default 
algorithm parameters, that is, a discrimination score cut-off of 0.08 and call zones of 0.8, were 
used to make all of the genotype calls. 
2.4.3 Mutation analysis 
Details of the PCR conditions and primers for mutation analysis AML samples is given 
in Table 2.1. Conditions are derived from previous publications for CEBPA (Snaddon, et al 
2003) and specific exons of FL T3 (exons 14-15 and 20) (Abu-Duhier, et al 2001, Kiyoi, et al 
1999). 
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Chapter 3 
Analysis of copy number and chromosomal abnormalities in AML by 
SNP array 
The purpose of this chapter is to explore the correlation between karyotype and 
abnormalities detected using SNP arrays. The potential abnormalities that may be detected are 
changes in copy number i. e. gains and deletions, and loss of heterozygosity (LOH), which may 
include the former, but also include recombination events and gene conversion. Large events 
should be confirmed by conventional cytogenetic analysis but small events may be 
undetectable. 
3.1 Materials and Methods 
Fifty-seven AML patient diagnostic DNA samples were genotyped using the 
Affymetrix 10K SNP mapping array as described in Chapter 2. Clinical characteristics of these 
AML samples are given in Table 3.1 and in detail in the Appendix. Where available, paired 
remission bone marrow was used for germ line comparison. Analysis was performed with 
GDAS software as previously described and Genome Orientated Laboratory File (GOLF) 
software (http: //bioinformatics. cancerresearchuk. org/cazier0l/Golf. html) to look for copy 
number changes and LOH. Conventional cytogenetics had been performed on these samples at 
diagnosis. The microarray data has been deposited in the National Cancer Biotechnology 
Information (NCBI) Gene Expression Omnibus (GEO)(2005) and are accessible through GEO 
Series accession number GSE7490. The numbering system for patient samples is described in 
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Appendix A, and relates to the numbering of samples in GEO series GSE7490. and GSE7210. 
Table 3.1 Characteristics of the 72 AML patients genotyped. 
Karyotype Number of patients 
Normal 41 
t(8; 21) 5 
t(15; 17) 4 
inv 16 3 
11g23 translocation 2 
-7 3 
+8 3 
Others 11 
FAB type 
M0 1 
M1 24 
M2 16 
M3 4 
M4 16 
M5 10 
M6 1 
M7 0 
Male: Female 39/33 
Median age 50 
3.2 Results 
3.2.1 Analysis of data from the SNP arrays 
3.2.1.1 Use of LOH scores from GDAS software 
The array uses hybridisation signals from 5 perfectly matched 25bp oligonucleotides, 
each displaced by 1 nucleotide, and 5 mismatched 25bp oligonucleotides. This is repeated for 
the alternate allele. The system also uses the antisense strand, so in total there are 40 
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oligonucleotides for each SNP. The allelotype is calculated from the relative allele signal from 
the sense and antisense strands. 
The algorithm used is called Modified Partitioning Around Medoids (MPAM). Initially 
a discrimination score (DS) is calculated for each pair of SNP alleles: 
DS= (P-M)/ (P+M) 
Where P= perfect match intensity 
M= mismatch intensity 
The median DS for each allele A and B, and for sense and antisense is calculated, and 
then the DS for the SNP is derived. If this is high enough, the SNP is passed and the relative 
allele score (RAS) is calculated. If not, the SNP is assigned a no call. The RAS is calculated 
from the average mismatch, M 
M-(MA-MB)/2 
Where MA= mismatch allele A intensity 
MB= mismatch allele B intensity 
Then relative intensity values for each allele A and B are calculated 
A=Max(PA- M, 0) 
B=Max(PB- M, 0) 
Where PA= Perfect match A intensity 
PB= Perfect match PB intensity 
Finally, an overall RAS value is given by 
RAS= A/(A+B) 
This is calculated for the sense and anti sense strands, RAS 1 and RAS2 respectively, 
and plotted on a graph of RAS I against RAS2. Figure 3.1 shows an example where two 
heterozygous SNPs are plotted. The medoid values (shown by the ovals indicating when a call 
is made) were determined from a set of 100 individuals of Caucasian, African-American and 
East Asian origin. If the RAS values fall within the appropriate medoid, then the appropriate 
call is made, if not then the SNP is assigned a no call. 
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Figure 3.1 MPAM mapping analysis window. 
An example of 2 heterozygous calls is shown, marked with a green and yellow point. The LOH 
value is derived from the distance between the two points. The centres of the medoids are 
marked with crosses. 
LOH can be determined by a change from heterozygous to homozygous between the 
germ line and leukaemia sample. This implies that there is a change in RAS values for the value 
to fall in a different medoid. The distance in RAS values between the two SNPs may be used as 
a surrogate for LOH, i. e. the difference of two squares between the two points. 
Figure 3.2 shows an example (patient sample 10) in which there is a deletion of the long 
arm of chromosome 7 (full karyotype 46, XX, dic(7; 22)(gl 1.2; g10), +8[10]). The values for non- 
informative homozygous SNPs do not change, so their LOH value is low, less than 0.2. 
Heterozygous SNPs that do not change, across the short arm of chromosome 7 also have low 
LOH values. However, across the deleted region, heterozygous SNPs have LOH values between 
0.3 and 1. There is variation in LOH values between individual SNPs, but taken as a whole they 
show the region of deletion has LOH. 
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Figure 3.2 Increased LOH values across the long arm of chromosome 7, due to deletion 
(patient sample 10). 
The lower diagram shows SNP allele calls (arbitrarily called A or B) along the chromosome in 
the leukaemia sample. Blue points represent homozygous calls and red points heterozygous 
calls (AA on the top line, BB on the bottom line and AB on the middle line. Grey points below 
the BB line are no calls). Increased LOH values between 0.5 and 1.0 are seen along the region 
of homozygosity (upper graph). Only informative calls are shown on the upper graph i. e. those 
heterozygous in the germline. Failed SNPs are also eliminated from this graph. The copy 
number ratio between the leukaemia and germline is shown on the lower graph. 
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This leukaemia sample also had trisomy 8. For heterozygous calls this gave a2 to 1 
ratio for one allele compared to the other, which would shift the RAS score and give an increase 
in the LOH score. However, this may not lead to a change in the genotype because the RAS 
values may still lie within the same medoid. Alternatively, the value may move to lie in between 
medoids, thus leading to an increase in the number of no calls. Figure 3.3 shows that the LOH 
scores increase to 0.2-0.4. 
This demonstrates that changes in allelotype, even changing to a no call, can be due to 
gain in the copy number. A further example is given in Figure 3.4, which has trisomy 11 and 13, 
where an increase in copy number for these chromosomes is associated with an increased 
number of no calls. 
Observing changes in the number of no calls of individual chromosomes is also 
important to identify LOH where there may be a significant contamination of germ line tissue. 
In that situation, there would be a mixture of the homozygous and heterozygous alleles, altering 
the RAS score, and therefore increasing the LOH score and the number of no calls, but not 
necessarily changing the allelotype called by the algorithm. 
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Figure 3.3 Moderately increased LOH values across chromosome 8 due to trisomy 8 (patient 
sample 10). Note the LOH values are less than 0.5, which is lower than the LOH values 
obtained from the deleted chromosome arm in Figure 3.2. 
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3.2.1.2 Use of GOLF software 
GOLF uses allelotypes generated by GDAS and plots them by chromosome location. It 
also plots changes in allelotype from the germ line, indicating LOH, and changes from 
heterozygosity to no call, the importance of which is described above. 
In addition, it calculates the copy number for an individual SNP, taking the mean of the 
perfect match intensities and subtracting the mean of the mismatch intensities. This absolute 
value is compared with the germ line to give a ratio indicating the actual copy number (a ratio 
of 1 is diploid, 0.5 is one copy, 2 is 4 copies etc. ). If no germline is available, then the 
alternative is to calculate the ratio of the intensity from the sample to the average intensity from 
a group of germ line samples. The intensity ratios are then plotted on a logarithmic scale by 
chromosome location. There is some noise in the measurement of copy number, which is 
largely dependent on variations on the PCR amplification step. If germ line and leukaemia 
samples were processed together, then there was less noise, presumably due to similar kinetics 
of the PCR reaction producing similar quantities of each DNA fragment. There was more noise 
when comparing the leukaemia sample against a group of normal DNAs; this would be 
expected because differences in the sequences of the genome and the occasion on which the 
assay was done would affect the PCR kinetics. Combining the results of several normal 
individuals by using the mean copy number for any given SNP would reduce the noise. Similar 
results have been noted by other groups (Nannya, et al 2005). 
There is also individual variation in signal value between adjacent SNPs. This may be 
because differences in the strength of hybridisation between different oligomers. This has also 
been found in CGH, but to a lesser degree, probably because the sizes of the BACs are much 
larger, and so hybridisation is more consistent. One method to reduce the variation is to take a 
mean of the signal values from adjacent SNPs. The larger number of adjacent SNPs used, the 
smoother the copy number graph and the easier it is to interpret. However, this method loses 
resolution, so small abnormalities may be missed. 
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GOLF also gives a broad indication of regions of homozygosity across the genome. It 
looks for regions of homozygosity defined by the number of contiguous homozygous SNPs, and 
compares the copy number of this region to the average across the rest the genome. This facility 
can produce a map of LOH, as was used in Chapter 5 (Figure 5.1, Figure 5.2 and Figure 5.3). 
3.2.2 Analysis of numerical chromosomal abnormalities 
Large regions of LOH that correlated with chromosome arm deletions and a decrease in 
copy number could be inferred from the relative allele score (RAS) of the SNPs in that region 
(Liu, et al 2003). Thus, in Figure 3.2, deletion of chromosome 7 can be seen from 
homozygosity for the whole of the chromosome and a reduction in copy number as compared 
with control DNA. 
Gains were observed as a change in copy number as well a change in allelotype. Figure 
3.3 shows an example in which there is trisomy 8. The copy number is increased along the 
whole length of the chromosome and there is a loss of heterozygous calls to no calls. If trisomic 
chromosomes consisted of 3 copies of the same parental chromosome then the chromosome 
would be completely homozygous. However, this result demonstrates that one of the parental 
chromosomes has been duplicated, and the other retained. For heterozygous calls, there is 
therefore a 2: 1 ratio of alleles. Depending on the signal intensity this led to retention of 
heterozygosity, a no call or homozygosity. 
Most of the samples had a clear correlation between the copy number and karyotypic 
changes. AMLs with known balanced translocations had no evidence of a change in copy 
number at the region of translocation confirming there was no loss or gain of genomic material 
at the break point, at least at this resolution. Most normal karyotype AMLs showed no change in 
copy number and no large regions of LOH. Some of the AMLs did show large regions of 
homozygosity without a change in copy number, but these shall be discussed in Chapter 4. 
Those AMLs that had chromosomal deletions had associated regions of LOH and a fall 
in copy number, as is detailed in Table 3.3. Only one case (patient sample 70) who had the 
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karyotype 45, XX, t(6,9)(q22.3; q34)/45, XX, t(6,9)(g22.3; g34), del(7)(q35) showed no evidence of 
a change in chromosome 7, despite having a blast percentage of 94%. Cytogenetic analysis 
relies on the analysis of the clone that will grow in culture for 24 hours, so it is likely that the 
majority clone did not have a deletion of chromosome 7 and did not grow, explaining its 
absence on the SNP array. Many karyotypic changes were not as simple as delineated in the 
karyotype. For example, GSM173409 had monosomy 9 by cytogenetic analysis, but only the 
long arm was deleted on SNP array, with the telomeric end of the chromosome also remaining 
(Table 3.3). Similarly, patient sample 34 had monosomy 7, but retained the proximal part of the 
long arm of chromosome 7 on the array. These results suggest that apparent whole chromosome 
deletions have more complex rearrangements than is revealed by conventional cytogenetic 
analysis. In a similar vein, patient sample sample 31 had a complicated rearrangement of 
chromosome 9, but from the array, the result was a deletion with LOH of a small part of the 
short arm of chromosome 9. The region is delineated by the heterozygous SNPs rs2383159 (at 
chromosome base pair location 20881855) and rs1758734 (base pair location 25253918). 
Amongst several genes within this region is CDKN2A or p16, and CDKN2B or p14, both TSGs 
involved the cell cycle, and both have been described to be epigenetically suppressed in AML 
(Christiansen, et al 2003, Linggi, et a! 2002). 
Several deletions were not identified by conventional cytogenetics at all. Two small 
interstitial deletions were observed at 5p (base pair 15872615-23071052) in patient sample 78 
and 7q (base pair 140586305-143189876) in patient sample 23 (see Table 3.3). The latter 
involves the T cell receptor (TCR) beta variable chain, so may be due to homologous 
recombination. TCR gene rearrangements are known to occur in some subtypes of AML 
(Chapiro, et a12006, Dupret, et a12005). Gain of lp was a recurrent abnormality detected by 
SNP array but not identified by karyotypic analysis (patient samples 16,37,38 and 78). The 
cytogenetics literature lists 87 examples of add(1)(p? ) (National Cancer Institute 2006), 
suggesting it could be a common abnormality, but not easily identified by cytogenetic analysis. 
Abnormalities of chromosome 19 were difficult to interpret. Sample 53 gives an 
example of trisomy 19 with an increase in copy number. However, GSM173413 shows an 
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anomalous fall in copy number associated with trisomy 19. Several other AML samples show 
apparent gain or deletion in the context of diploid chromosome 19 on cytogenetic analysis. 
Problems with the interpretation of copy number of chromosome 19 have previously been noted 
with CGH (Kallioniemi, et al 1994). The complete sequence of chromosome 19 shows it is the 
densest number of genes of any chromosome with large numbers of repetitive sequences 
(Grimwood, et al 2004). On the array, chromosome 19 has the lowest density of SNPs. 
Together, these problems mean interpretation of copy number must made with caution. Similar 
problems can occur with the smaller chromosomes, particularly 21 and 22. A smaller number of 
SNPs means that if the copy number of only a few of them is raised or decreased due to noise, 
the mean copy number of the chromosome is altered, and the copy number may be incorrectly 
interpreted as amplified or deleted. 
3.2.2.1 Single SNP changes 
Several cases, when compared to their remission sample, had single SNP loci that had 
LOH, and some also appeared to gain heterozygosity. It would be valuable to find genuine 
small regions of LOH, as they would give the location of putative oncogenes. However, gains of 
heterozygosity would be difficult to explain; it would suggest the nucleotide had mutated. The 
rate of reproducibility of allelotypes on the array is 99.96% (Affymetrix 2003), which would 
mean one may expect 4 or more SNPs to be discrepant due to noise on any given array. 
Repeating the assay for two samples (N and M) showed a different result for some of these 
discrepant SNPs i. e. homozygosity instead of heterozygosity, implying one of the results was 
wrong. 
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Table 3.2 Single SNP changes. The Affymetrix (Affy) array genotypes were assayed again by 
Pyrosequencing (Pyro). 
Paired patient samples SNP ID 
Germ Line / 
Remission 
Leukaemia 
Remission Diagnosis Affy Pyro Affy Pyro 
44 10 rs1944130 C/T C/C C/C C/C 
28 27 rs910952 A/A, G/A* A/A A/A A/A 
89 16 rs910950 G/A A/A A/A A/A 
95 9 rs1977697 A/G G/G G/G G/G 
89 16 rs1977697 A/G G/G G/G G/G 
105 14 rs1977697 A/G G/G G/G G/G 
96 32 rs2123077 T/C T/C T/T, T/C* T/C 
89 16 rs278341 T/C T/C T/T T/C 
28 27 rs864179 T/C, C/C* C/C T/C, C/C* C/C 
96 32 rs864179 T/C C/C T/C, C/C* C/C 
105 14 rs864179 T/C C/C C/C C/C 
41 40 rs278341 T/C C/C C/C C/C 
*Repeated array results 
In order to confirm (or refute) these genotypes, Pyrosequencing was performed (Table 
3.2). The technology used in Pyrosequencing relies on the release of a pyrophosphate molecule 
when a dinucleotide triphosphate (dNTP) is incorporated into the DNA sequence by DNA 
polymerase. The dNTPs are added to the reaction one at a time, so it is clear which particular 
nucleotide (A, T, C or G) is incorporated. The pyrophosphate is converted to adenine 
triphosphate (ATP) by ATP sulfurylase, and ATP produces fluorescence by being the substrate 
for luciferase. The fluorescence is proportional to the amount of nucleotide incorporated. 
Sequencing this way is a more accurate way of analysing the SNP change than the Affymetrix 
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hybridisation technology. In most cases the discrepant Affymetrix result was heterozygous and 
all were transversions rather than transitions. I conclude that single SNP changes cannot be 
relied upon to determine LOH. 
There are a number of explanations for the failure of individual SNPs to give the correct 
genotype. There were a few situations where an array with a good call rate (>95%) had only 3-4 
SNPs that were not concordant. If the tertiary structure of a particular sequence has more 
likelihood of being degraded by the DNAase at the fragmentation step then this would change 
the balance of transcripts. The hybridisation process may have problems with non-specific 
binding, as it is at a relatively low temperature (47°C), and the washing of the array is done at a 
much lower temperature i. e. room temperature. It needs these values so that many probes with 
different optimal hybridisation temperatures may bind specifically. However, it may be at the 
expense of occasional non-specific binding. 
3.3 Summary and conclusions 
The Affymetrix IOK SNP arrays are able to provide accurate genotype information that 
is able to detect regions of LOH that are only a few megabases in length. The copy number data 
is consistent with conventional karyotypic analysis, but because of the improvement in 
resolution also provides additional data on the breakpoints of deletions, and clarifies interstitial 
deletions and complex rearrangements. By understanding the how the technology works, the 
change in allelotypes, from heterozygosity to homozygosity or no call can be used with copy 
number information to interpret genetic aberrations in the leukaemia. 
Many of the limitations in interpreting the data are due to the relatively low resolution 
of the l OK array, compared to current systems using hundreds of thousands of SNPs. Arrays of 
this size can identify genes within regions of only a few hundred kilobases (Mullighan, et al 
2007). However, one of the main advantage of the SNP array is to identify regions of LOH in 
the absence copy number change, due to somatic recombination events, and these shall be 
discussed in the next chapter. 
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Acquired uniparental disomy in AML 
4.1 Introduction 
One of the hallmarks of human cancer is the acquisition of chromosomal abnormalities. 
The recurrent abnormalities, such as translocations, have been particularly informative in 
establishing the pathogenesis of haematological malignancies. As discussed in chapter 1, the 
prognosis of AML correlates closely with the karyotype of the leukaemic cells, but a large 
proportion of AML has either a normal karyotype (NK) or non-recurrent chromosomal 
abnormalities. 
Expression profiling studies have shown that NK AMLs form a discrete subgroup. 
These leukaemias have a characteristic upregulation of certain homeobox genes (Debernardi, et 
al 2003). Several single gene mutations have been documented in AML, and some, such as 
FLT3 and NPMI mutations, have been associated with the presence of a normal karyotype. 
However, for many NK AML patients, the underlying pathogenesis remains uncertain. Any 
alternative techniques demonstrating the heterogeneity of this large group presents the 
opportunity of additional risk stratification, might allow for a more rational selection of therapy, 
and shed further light on the pathogenesis of the disease. 
Because SNP arrays can detect copy number changes as well as LOH, they can identify 
abnormalities where there is no net change of genetic material, unlike aCGH. Although LOH 
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often implies deletion, there are large-scale genetic events that would leave the copy number 
unchanged. Gene conversion is an unequal crossover event, such that one allele becomes the 
same as the other, and would lead to a region of LOH. Mitotic recombination is an equal cross 
over event that leads an exchange of material between parental chromosomes (Figure 4.1). At 
cell division, this subsequently leads to cells that are homozygous for the region distal to the 
recombination. If one of these cells has a selective advantage, LOH would be detected across 
the homozygous region. 
In this chapter, it is demonstrated that high resolution SNP genotyping can identify 
large unexpected regions of LOH, with no change in copy number, which results from mitotic 
recombination leading to acquired partial uniparental disomy. 
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Figure 4.1 Diagrammatic representation of mitotic recombination. The long arm of the 
chromosome has exchanged material between the two parental chromosomes and on cell 
division two clones are produced each homozygous for the long arm distal the recombination 
event. The "* " represents a gene that has a selective advantage when homozygous. 
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4.2 Materials and Methods 
4.2.1 Sample Selection 
AML diagnostic samples, and remission paired samples where available were obtained 
with ethical approval and patient consent and stored frozen in the cell bank at St. Bartholomew's 
hospital as described in Chapter 3 
4.2.2 10K GeneChip Assay 
Methodology is as described in Chapter 2. Data was analysed using GOLF software 
and deposited in GEO as described in Chapter 3. 
4.2.3 FISH Assay 
FISH was performed on metaphase and interphase cells harvested from bone marrow 
aspirates following short-term culture. FISH probes were directly labelled with the 
fluorochrome (Vysis, Abbott Laboratories, Illinois, USA) and target slides were co-denatured 
with the probe at 70C for 5 mins. Hybridisation was achieved by incubation at 37C for 24 
hours and post hybridization washes were performed according to manufacturer's protocol. 
Slides were counterstained with 4,6-diamino-2-phenyl-indole and screened using a Leica 
DMXRA microscope (Leica Imaging Systems, Cambridge, UK) fitted with a COHU CCD 
camera. MacProbe V4.1.1 CGH software (PSI/Applied Imaging) was used for the analysis. 
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4.2.4 Bisulphite sequence analysis 
The DNA methylation status of the CTCF binding site 6 (CBS6), (GenBank accession 
no. AF125183; nucleotides 7855-8192) included in the H19 differential methylated region on 
l lp, was assessed by bisulphite genomic sequencing. The genomic DNA of three samples, two 
carrying the UPD at the 11p15 site and one control, was amplified by PCR after bisulphite 
treatment, as previously described (Cui, et al 2002) using the primers: h19 fl, 5'- 
GAGTTTGGGGGTTTTTGTATAGTAT-3' and h19-rl, 5'- 
CTTAAATCCCAAACCATAACACTA-3', followed by h19-j2, 
5'-GTATATGGGTATTTTTGGAGGT-3'and h19-r2, 
5'-CCATAACACTAAAACCCTCAA-3'. The PCR products were directly sequenced. 
4.2.5 Mutation analysis 
Primers and precise amplification conditions are as described in Chapter 2. Mutation 
screening was done for the entire coding region (CCND3, CDKN2A, CDKN2B, PU-1, and 
CEBPA) or specific exons [WTI (7-10), FLT3 (exons 14-15 and 20), RUNX1 (exons 3-5), and 
MLL (PTD)] as described in Chapter 2. PCR products were sequenced directly or cloned by 
TOPO TA cloning (Invitrogen Ltd., Paisley, United Kingdom), plasmid DNA extracted and 
sequenced by use of an ABI 377 DNA sequencer (PE Applied Biosystems, Foster City, CA). 
For direct sequencing, unincorporated primer was removed by ultrafiltration using a Centricon 
YM-100,000 filter device (Millipore). Sequencing data were analyzed using DNASTAR, Inc. 
(Madison, WI). 
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4.3 Results 
4.3.1 Identification of acquired UPD 
A high-resolution genotype analysis was performed on DNA from 64 presentation AML 
samples for which full karyotype information was available. The range of leukaemias examined 
was typical of AML and included those with a normal karyotype and with the translocations 
resulting in chimeric transcription factors such as t(8; 21), inv(16), t(15; 17) and I1g23. Using 
the 10K SNP array (Affymetrix, Inc., Santa Clara) (Matsuzaki, et a! 2004), a mean call rate of 
93.3% was obtained resulting in more than 10,000 SNP genotype calls per sample. 
Large unexpected regions of homozygosity were observed in 15 of 72 AMLs from a total 
of 72 (20.8%) (Table 4.1). These regions ranged in size from 16 to 113 million base pairs and 
would have been visible in the karyotypes had they been due to deletion. The signal values were 
calculated within the regions of LOH as described in the legend to Table 1 (Bignell, et a12004, 
Zhao, et a! 2004). In every example, the SNP signal values were indicative of two copies (Table 
4.1). The presence of two copies has been confirmed by fluorescence in situ hybridisation 
(FISH) in the 4 cases analysed. In order to assess whether these regions of homozygosity were 
restricted to the leukaemic clones, DNA from five available remission bone marrow samples 
(for samples paired with AML samples 35,10,69,40 and 49 in Table 4.1) was subjected to 
SNP genotype analysis. The SNP call data (deposited at the Gene Expression Omnibus under 
accession number GSE7490) demonstrated clearly that the homozygosity seen in the leukaemic 
DNA was not present in the respective remission bone marrow DNA. It was also evident that all 
of the SNP calls in the homozygous regions were concordant with the equivalent calls in the 
remission bone marrow DNA. A detailed comparison between leukaemic DNA and remission 
DNA for patient sample 10 is presented in Figure 4.2 for relevant chromosomes. The large 
region of homozygosity on chromosome 11 q is illustrated as a fall in the ratio of heterozygous: 
homozygous calls (Figure 4.2A). The ratios of leukaemia versus remission signal values were 
calculated along the length of chromosome 11 as described (Table 4.1). There was no 
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significant drop in signal ratio values for the region of homozygosity indicating that the 
leukaemia had a normal copy number for chromosome 11. 
Table 4.1 The 12 leukaemias exhibiting UPD, listed with their respective karyotypes. 
In patient sample 41, the presence of the PML-RARa gene fusion was confirmed by FISH in the 
majority of interphase cells. In total, 64 diagnostic acute myeloid leukaemia bone marrow or 
peripherally taken blood samples from the frozen tissue bank at St Bartholomew's Hospital 
were analysed using the IOK SNP array that encodes approximately 11,500 SNP loci 
(Affymetrix, Inc., Santa Clara) (Matsuzaki, et a! 2004). For each SNP on the chip there are 20 
probe pairs, 10 for allele A and 10 for allele B. A probe pair contains a perfect match (PM) and 
a mismatch (MM). The signal value is calculated as the average intensity difference between a 
perfect match and a mismatch for all probe pairs, and is given by 1/20, where PAT is the 
intensity of perfect match of pair i and MMi is the intensity of mismatch for the same pair. The 
signal value ratio is the ratio of mean signal within UPD region divided by mean signal outside, 
for the same chromosome. For patient samples 79 and GSM173396 we have calculated the 
ratio of mean signal of chromosome 13 to the mean of the mean signal of all other 
chromosomes. All the statistical analysis is done with R. Abbreviations: ND, not done. 
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Since this leukaemia had a rearrangement resulting in a deletion of 7q, dic(7; 22), an 
identical calculation was performed for chromosome 7. As shown in Figure 4.2B there was a 
large homozygous region on 7q but, in contrast to the results above, the leukaemia to remission 
signal ratio values fell to approximately 0.5 in the homozygous region. A DNA probe for the 
MLL gene (11g23), which lay within the homozygous region, was used in FISH experiments to 
both metaphase and interphase cells from this leukaemia. This confirmed the presence of two 
copies of 11g23 in metaphase and interphase cells (Figure 4.2C). It was therefore concluded that 
these regions of homozygosity (Table 4.1 and Figure 4.2) represented somatically acquired loss 
of heterozygosity (LOH), due to the presence of partial uniparental disomy (UPD), which was 
restricted to the leukaemic clone. 
This study demonstrates that the acquisition of partial uniparental disomy is a relatively 
common event in adult AML and selected examples are illustrated in Figure 4.3. There appears 
to be a non-random distribution of these events with 4 examples of UPD13q, 3 examples of 
UPD1Ip, and 2 examples each of UPD11q and UPD6p. 
It was also apparent that the points of recombination are clearly different in all examples. 
In 12 of the 15 examples, the region of LOH began within a chromosome arm and continued to 
the telomere implying that this phenomenon is due to mitotic recombination. In two examples, 
the entire chromosome 13 was homozygous (patient samples 79 and GSM173396) suggesting 
either a non-disjunction event followed by chromosomal duplication or a recombination close to 
the centromere. The one example (patient sample 65) of interstitial LOH could be due to a 
double crossover event affecting I Ip. It is interesting to note that there was only one example of 
UPD in the leukaemias with balanced translocations, although a larger series would be need to 
be examined to confirm this low frequency. 
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Figure 4.2 Analysis of UPD in patient sample 10. 
Figure B 
11 
11 
10 
A. The ratio of the number of heterozygous to homozygous calls in a running window of 20Mbp 
was calculated. The LOH score (red) was calculated by dividing the above ratio in the 
leukaemia sample by the same ratio in the remission sample. The signal score (black) is 
calculated as the ratio of the mean signal (Table 4.1), in a running window of 20Mbp, between 
leukaemia (sample 10) and remission (paired sample 44). Results for analysis of chromosome 
11 in upper panel and for analysis of chromosome 7 in lower panel. 
B. FISH hybridisation of a two-colour probe for the MLL gene. The hybridisation signals show 
two copies of the MLL gene in interphase cells from patient sample 10. 
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4.3.2 Imprinted genes in the region of UPD 
The expression of imprinted genes in the homozygous regions would be expected to be 
profoundly affected. Congenital disorders associated with UPD have been linked to a single 
parental origin, e. g. Beckwith-Weidemann syndrome and paternal UPD of 11p 15 (Henry, et a! 
1991), suggesting the parental pattern of methylation is important to the pathogenesis of such 
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disorders. In a similar manner, any parental bias in the UPD seen in this study would be 
evidence for the role of imprinted genes. The leukaemias studied here are from adult patients 
and parental DNA samples were unavailable. The H19 gene, which encodes an untranslated 
RNA and is located at lip 15, is normally methylated only on the paternal allele (Cui, et al 
2002). Two leukaemias exhibited UPD including l 1p 15 and the methylation status of the H19 
gene was therefore determined by bisulphite sequencing. As shown in Figure 4.4A one 
leukaemia with UPD1lp (patient sample 35) exhibited a homozygous methylated pattern and 
therefore paternal H19 gene, while the other example of UPD11p (patient sample 37) showed a 
homozygous non-methylated and therefore maternal pattern (Figure 4.4B). A control leukaemia 
with heterozygous SNP calls for llp showed a mixed methylated and non-methylated pattern 
(Figure 4.4C). These data show that the homozygosity seen on l lp is not restricted to a single 
parental origin. 
4.3.3 Homozygous mutations in the region of UPDs 
Another consequence of UPD, that is not parentally dependent, could be to render one of 
the daughter cells homozygous for a pre-existing mutation. In a previous analysis (Snaddon, et 
a12003) one of the leukaemias studied here (patient sample 49 in Table 4.1) was shown to be 
homozygous for a CEBPA mutation and FISH demonstrated 2 copies of the CEBPA gene. This 
gene is located at 19g13.1, within the area of UPD and we conclude that the mutation occurred 
prior to the UPD. We can therefore speculate that an important consequence of mitotic 
recombination could be to render pre-existing mutations homozygous. Eight different 
chromosomal regions were shown to be affected by UPD in this study and this suggested that 
there would be at least this number of mutational targets. 
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Figure 4.4 DNA methylation of the CTCF binding site 6 (CBS6), included in the HI 9 DMR. 
Part of the sequence obtained with h19r2 oligonucleotide is shown and three CpG sites are 
indicated by arrows. On top is shown the genomic DNA sequence before bisulphite treatment. 
1) In the first sample (patient sample 35, Table 4.1) all the cytosines in the CpG dinucleotides of 
both alleles remain unchanged, therefore methylated, indicating homozygosity for the paternal 
allele. 2) In the second sample (patient sample 37, Table 4.1) all the cytosines in the CpG 
dinucleotides of both alleles are converted in thymine by the treatment (adenine in the 
chromatogram as the reverse strand is shown), indicating homozygosityfor the maternal allele. 
3) In the control sample both alleles are present as shown by the two overlapping peaks, 
indicating a state of heterozygosity. 
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To investigate this phenomenon further, we selected 13 of the primary AMLs with 
uniparental disomy encompassing regions known to harbour genes potentially mutated in AML 
(Table 4.2). Sequence analysis was done on nine genes in the appropriate leukaemias. Mutations 
were detected at four distinct loci (WTJ, FLT3, CEBPA, and RUNXI) in 7 of the 13 leukaemias 
examined. In all cases, sequence analysis indicated a homozygous mutation with no evidence of 
the wild-type sequence. In Figure 4.5, the sequence traces showing a homozygous insertional 
mutation of the WTI gene are illustrated along with the homozygosity map for chromosome 11. 
Similarly, a homozygous single-base insertion of the RUNXI gene is shown with the concurrent 
homozygosity of 21q. It was notable that uniparental disomy of 13q was associated with 
homozygous internal tandem duplication mutation of FLT3 (FLT3-ITD) in four separate cases. 
Table 4.2 Regions of UPD and associated homozygous gene mutations. 
Patient 
sample 
35 
49 
79 
76 
GSM 
173434 
GSM 
173396 
GSM 
173397 
37 
65 
10 
69 
40 
7 
Karyotype UPD Gene Mutation 
46, XY 
46, XY 
46, XY 
11p13-1 lpter WTI, Pull 
19g12-19gter CEBPA 
21g21-2lgter RUNXI 
1584 insl6bp 
(WTI) 
1038ins57bp 
(CEBPA) 
970 insA (RUNXI) 
46, XX 13q FLT3 ITD 21bp (FLT3) 
46, XY t(6; 9) 13q FLT3 
46, XX 13q FLT3 
46, XX 
46, XX 
46, XX 
46, XX, dic(7; 22) 
(q 11.2; q 10), +8 
48, XY, +3, +10 
46, XX 
46, XY, der(12)t(1; 12) CDKN2A, 
(q 1 l; p 11.2)/46, XY 
9pcen-9pter 
CDKN2B 
13q FLT3 
ITD 63bp (FLT3) 
ITD 36bp/ 39bp* 
(FLT3) 
ITD 108bp (FLT3) 
l lpl l-l lpter WTI, PU. 1 None 
l lpl l-l lpl4 WTl, PU. 1 None 
11g12-llgter MLL None 
6p21-6pter CCND3 None 
6p 11-6pter CCND3 None 
9pcen-9pter None 
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Figure 4.5 Display of UPD on Ilp and 21q in two AML samples. Heterozygous calls (red) and 
homozygous calls (blue). The corresponding sequencing traces showing I584ins16bp WTI and 
970insA R UNXI homozygous mutations. WT and RUNXI duplicated segments (underlined in 
orange). 
4.4 Discussion 
There is no a priori reason why UPD should be restricted to AML, and indeed the use of 
microsatellite markers has suggested UPD in other clonal haematological disorders such as 
polycythaemia vera (Kralovics, et a! 2002). Several groups have shown that a frequent 
mutational target in myeloproliferative disorders such as polycythaemia vera is the JAK2 gene, 
located within 9p (Baxter, et al 2005, James, et a! 2005, Kralovics, et al 2005, Levine, et a! 
2005). Loss of heterozygosity at 9p is frequently observed in association with mutations to the 
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JAK2 gene and has been shown to be due to mitotic recombination (Kralovics, et al 2005). 
Thus, mitotic recombination is playing a role in both myeloproliferative disorders and in AMLs, 
although clearly different mutational targets are involved. 
A study of childhood ALL has shown the consistent loss of maternal alleles on 9p 
without evidence of cytogenetic deletions in the same region (Morison, et a12002). Recurrent 
acquired UPD of chromosome 9p in ALL was recently confirmed using 250K SNP arrays, and 
many cases have homozygous deletions of CDKN2A (Kawamata, et a! 2008). In solid tumours, 
UPD has been observed in breast cancer (Murthy, et al 2002), uveal melanoma (White, et al 
1998), Wilm's tumours (Shearer, et al 1999), retinoblastoma (Hagstrom and Dryja 1999) and in 
tumours associated with Beckwith-Weidemann syndrome (Henry, et al 1991). A SNP array 
study in basal cell carcinoma has shown that acquired uniparental disomy of chromosome 9q is 
common and associated with mutation of the PTCH gene (Teh, et a! 2005). 
Mitelman et al have shown that the numbers of balanced chromosomal rearrangements 
are similar when haematopoietic malignancies are compared to solid tumours (Mitelman, et al 
2004) suggesting that general pathogenic mechanisms are common to all cancers. In this context 
it is interesting to note that a recent study of solid tumour cell lines using SNP genotyping has 
suggested that mitotic recombination may be playing a role since regions of homozygosity were 
observed which corresponded to normal copy number values (Bignell, et al 2004). Because 
UPD is undetectable by cytogenetic analysis, its frequency in cancer may be much higher than 
previously thought. 
Mitotic recombination, which has been shown to occur at a frequency of 104-10"S in 
normal human and mouse cells (Tischfield 1997), results in a cell population mosaic for the 
recombined chromosomes. The UPD seen in leukaemias must represent the clonal outgrowth of 
one of the daughter cells due to a selective advantage. In the general population, inherited UPD 
is a rare occurrence (Karanjawala, et al 2000). Studies using the HLA locus have shown that 
there is inter-individual variation in the rate of mitotic recombination (Holt, et al 1999) and that 
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it increases with age. Recent studies using a mouse Trp53+1 BALB/c strain showed that mitotic 
recombination played a major role in generating LOH at the Trp53 locus in a series of 
mammary tumours (Blackburn, et a! 2004). Furthermore, the high rate of mitotic recombination 
was shown to be a dominant trait in crosses with the C57BL/6 strain. It may be speculated that 
the presence of UPD in a cancer may identify individuals with a higher rate of mitotic 
recombination and that this could be genetically determined. 
The presence of a mutation and the absence of the wild-type sequence has previously 
been reported in AML for WT1 (Miyagawa, et al 1999), CEBPA (Leroy, et al 2005), and 
RUNX1 (Silva, et al 2003, Smith, et al 2005). Such a situation could arise by several 
mechanisms, including the deletion of wild-type allele to yield a hemizygous state, amplification 
of the mutant allele, or mitotic recombination. Without accurate copy number information, it has 
been difficult to distinguish between these possibilities. The high degree of association between 
uniparental disomy and homozygous mutation presented here suggests that uniparental disomy 
may account for a substantial proportion of cases exhibiting a lack of the wild-type allele. 
Indeed, it has been previously suggested that homozygous RUNXI mutations in leukaemias 
could be due to mitotic recombination (Silva, et a! 2003). Because relatively large regions of the 
genome are involved, there may be more than one potential mutational target in a given region 
of uniparental disomy. An example of a WT1 mutation was observed in one of the three 
examples of UPDI lp suggesting other potential targets in this region. Similarly, because no 
mutations were detected in the CCND3, CDKN2A, CDKN2B, and MLL genes, our data would 
suggest that there may be other targets in UPD6p, UPD9p, and UPD 11 q, respectively. 
FLT3-ITD mutation in the heterozygous state is a recognized poor prognostic risk factor 
for AML. Additionally, the loss of the wild-type FLT3 allele in leukaemias with a FLT3 
mutation in about 10% of patients with normal karyotype AML is associated with a worse 
outcome (Thiede, et al 2002, Whitman, et al 2001). Hence, the association between loss of the 
wild-type FLT3 allele and UPD13q could suggest that the presence of uniparental disomy may 
be linked to clinical outcome. The close proximity of FLT3 to the centromere and the small 
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number of SNP markers proximal to FLT3 on chromosome 13 means that in some cases, we 
cannot exclude the possibility of mechanisms other than mitotic recombination leading to 
uniparental disomy of chromosome 13. This could include non-disjunction followed by 
chromosome duplication. Mitotic recombination is clearly the case for WTI, RUNXI, and 
CEBPA mutation (Figure 4.5) and suggests that mutation precedes mitotic recombination that 
acts to remove a normal copy of a gene and replace it with a mutated copy. 
The discovery of widespread, somatically acquired, UPD in leukaemias has other 
potentially important biological and clinical implications. Several recent studies have suggested 
that there are allelic differences in gene expression from non-imprinted autosomal genes that are 
heritable (Lo, et al 2003, Yan, et al 2002). Mitotic recombination leading to UPD may thus 
affect the expression of certain genes within the homozygous regions. Hence, in addition to 
rendering pre-existing mutations homozygous, mitotic recombination may also exert subtle but 
critical effects on gene expression. 
In summary, this study has identified hitherto unrecognised abnormalities in 20% of 
normal karyotype AMLs. The frequency of the occurrence of UPD and the degree of 
consistency with which it occurs suggests it is a critical event in the development of leukaemia 
and will be important in the classification of AML. The event gives a marker of disease where 
none was previously available, and an opportunity to look for molecular targets. Although the 
prognostic consequences of this phenomenon are currently uncertain, given the importance of 
other frequent chromosomal events in AML, larger studies to assess the clinical significance of 
mitotic recombination are required. 
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Chapter 5 
A pilot study to map homozygosity in an unselected group of patients 
with AML 
5.1 Introduction 
The discovery of acquired UPD in a group of diagnostic AML samples raises a number 
of issues. The incidence of acquired UPD was found to be 20%, but a more accurate assessment 
could be made from a larger prospective study. The sample set from Barts was biased because 
the patients had previously been analysed for mutations and gene expression, and thus were 
chosen because of sample availability and by karyotype. Although this gave an assessment of 
the incidence of uniparental disomy and other copy number changes it is not necessarily 
accurate. A recent smaller study (Gorletta, et al 2005), gave the incidence of acquired UPD as 
15%. 
Acquired UPD was found in non-random chromosomal regions, some of which were 
associated with homozygous gene mutations. The other UPDs could have unidentified genes 
within the homozygous region. However, these are large regions of LOH, making identification 
of potentially mutated genes very difficult. A map detailing regions of LOH using a large 
number samples could delineate minimal regions of LOH, and putative oncogenes or TSGs 
could be identified. 
Some of the gene mutations associated with UPD have prognostic implications, e. g the 
presence of the FLT3 ITD mutation with a loss of the wild type gene confers a poor prognosis 
(Thiede, et al 2002). With a large enough sample set, and sufficient follow up, it would be 
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possible to make correlations with prognosis. 
As it would be time consuming to prospectively obtain sufficient samples for analysis, 
the alternative was to use samples from previous national studies on AML. This has the 
advantage that the AML patients were prospectively entered into the trial, although because the 
analysis is being done retrospectively, there may still be some bias depending on the availability 
of samples for analysis. However, the patients have many years of follow up, which gives good 
survival data. The study samples from MRC AML10 are a well-characterised sample set that 
has been used in studies investigating cytogenetics, gene mutation status and prognosis. 
The study required would be large, and to estimate the number of samples needed to 
give an answer to questions of prognosis, a pilot study was required. Therefore, the purpose of 
this study was to show there were a significant proportion of patients with acquired UPD, and to 
assess how many patients would be required for a larger study. 
5.2 Methods 
Samples with DNA available at diagnosis were obtained from the Medical Research 
Council AML10 study. This study recruited from May 1988 to April 1995. In brief, this trial 
was designed to randomise patients between using daunorubicin and cytarabine with or without 
etoposide at induction chemotherapy. For good risk patients, there was a further randomisation 
between completing four or five courses of chemotherapy. For standard risk patients, there was 
a randomisation between four or five courses of chemotherapy, or using a transplant as the 
fourth or fifth course. The first 93 patients for whom DNA samples were available were 
analysed using the Affymetrix 10K 2.0 Mapping Array as described in Chapter 2. Six samples 
failed to amplify sufficiently during the PCR amplification stage, leaving 87 samples that were 
successfully hybridised. Comparison was made with cytogenetic data, which was available for 
74 patients. The primary SNP microarray data have been deposited in the NCBIs Gene 
Expression Omnibus (GEO, http: //www. ncbi. nlm. nih. gov/projects/geo/) and are accessible 
through GEO series accession number GSE8721. 
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Remission germ-line DNA was available for only three patients in the pilot group, so 
only these could be assessed definitively for LOH. Regions of LOH due to deletion could be 
assessed by correlation of copy number and homozygosity. For UPD, a criterion of a minimum 
of 30 contiguous homozygous SNPs was used to define a likely region. The mean inter SNP 
distance on the array is 258kb, giving a minimal size of UPD of 7.7Mb. By decreasing the size 
of a homozygous region, more regions are detected, but many of these will be germ-line rather 
than somatically acquired. On analysis of germ-line DNA (blood) from 16 patients with 
squamous cell carcinoma of the skin (Purdie, et al 2007), only one region of homozygosity 
larger than this size was found, suggesting this to be a reasonable criterion. Additionally, 
comparison was made with 62 long haplotypes that are described from trios (two parents and 
off-spring) from the HapMap project (International HapMap Consortium 2005). If any of these 
haplotypes were inherited from both parents, the child would be homozygous across that region. 
Only four long haplotypes were discovered that were larger than 7.7Mb; two of these all lay 
across centromeric regions, which are known to be less polymorphic, and one lay on the X 
chromosome which has been found to have a greater number of long haplotypes than other 
chromosomes. 
DNA copy number was assessed by comparing the SNP signals of a panel of non- 
leukaemic DNAs, obtained from the germ line (DNA from venous blood) of a group of patients 
with squamous and basal cell carcinoma of the skin. 
53 Results 
Allowing for balanced translocations, which cannot be detected by SNP array analysis, 
there were 44 chromosomal aberrations that were confirmed by cytogenetic analysis. SNP array 
information gave an additional 48 abnormalities. 
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5.3.1 Mapping regions of LOH (Figure 5.1) 
There were 68 regions of LOH detected in 42 patients. Of these, 27 were identified as 
deletions, 39 were UPDs and 2 were homozygous chromosomal gains. 9 UPDs extended to the 
telomere (telomeric UPDs), implying that a single mitotic recombination had occurred. Fifteen 
of the UPDs were interstitial, implying a double cross-over event. Six interstitial UPDs 
extended across the centromere of the chromosome, suggesting these may be germline events, 
i. e. homozygously inherited long haplotypes. 
Both of the homozygous gains involved the long arm of chromosome 11. One of the 
gains affected two regions of l1 q, and also involved a telomeric deletion, suggesting that this is 
actually a complex rearrangement. These homozygous gains may be due to loss of the other 
parental chromosome, or due to the relative increase in the number of copies of one of the 
parental chromosomes compared to the other. The relatively high copy number may have 
affected the MPAM algorithm that calculates the allelotype. Using an alternate algorithm 
(Huentelman, et al 2005), heterozygous calls were detected, suggesting that the alternate 
parental chromosome was not lost. 
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Figure 5.1 Map of homozygous regions greater than 30 consecutive SNPs in length. Green 
represents deletions, black represents disomy and red represents gains. Details of each 
abnormality are in Table 5.2. 
Recurrent regions of UPD are shown in Figure 5.1. Regions of UPD that had previously 
been observed in the previous study included chromosome 11, both p and q arms, and 
chromosome 13. The regions of UPD 11 p included the WTI locus, which had been mutated in 
other AML samples with UPDI lp. Similarly, the regions of UPD13 included the FLT3 locus, 
suggesting these samples may have mutations of FLT3. New regions identified with recurrent 
UPDs included chromosome 2p in two patients and 16q in two patients. The location of the 
point of recombination was close to each other for both the AML samples with UPD2p. The 
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prevelance of UPD in this group of patients was 32%, however if only patients with telomeric 
UPDs were considered, as were mostly described in the previous study, there were only 13%. 
Table 5.1 Recurrent regions of UPD or copy number change 
Chromosomal abnormality Frequency 
Gain 1p 2 
UPD 2p 2 
UPD 4q 3 separate sites 
Del 5q 3 
Del 7 5 
UPD 8q 3 separate sites 
Gain 8 8 
UPD l lp 2 
UPD 11 centromere 2 
UPDIIq 3 
Gain 11 q 2 
Gain 12 2 
UPD 13 4 
Gain 13 4 
UPD 16q 2 
Del 18 2 
Del20q 3 
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Although the regions of interstitial UPD were large, without germline material, it would 
be difficult to establish if they are somatically acquired. Three examples of paired diagnosis and 
remission samples are shown in Figure 5.2. Acquired regions of homozygosity are shown in 
patient 479 on chromosome 11, and in patient 931 on chromosomes 4 and 13. Chromosomes 11 
and 13 in the two patients show clear regions of LOH for many informative loci across the 
regions of homozygosity. Chromosome 13 includes the locus for FLT3, and the deletion on 
chromosome 11 includes the locus for WTI. However, for chromosome 4, although the length 
of the region of homozygosity is more than 30 SNPs, on comparison with the germ line, there is 
only a single SNP with LOH. With only one SNP that is informative, we cannot rule out noise 
in the genotype calling, so it is possible that this is not an acquired region of UPD. 
Chromososome 9 and 16q on 309 and 931 respectively are demonstrated to be germline regions 
of homozygosity. The former is across the centromere of chromosome 9, which suggests this 
could be a long haplotype. Patient 931 was found to have a deletion of 16q on cytogenetic 
analysis at diagnosis. SNP array analysis found no fall in copy number, although there was a 
region of homozygosity observed. This suggests that the 16q aberration is more complex than a 
simple deletion. The remission sample does not have the 13q UPD abnormality, but retains the 
16q abnormality, which suggests either the 16q aberration is in the germline, or else there is a 
persisting clonal population in the marrow at remission. Individuals with congenital deletions 
of this region (which extends from 16g21 to 16g22.3) are known to have microcephaly and 
learning disabilities amongst other problems (Monaghan, et al 1997), but whether this patient 
had this syndrome is unknown. 
5.3.2 Mapping of copy number changes (Figure 5.3) 
Deletions smaller than 30 SNPs could be identified by identifying regions with a fall in 
copy number superimposed on a region of homozygosity. Except for the two regions on 
chromosome 11 discussed above, no other regions of copy number gain were associated with 
LOH. Combined with the homozygosity map (Figure 5.1), the map of copy number alterations 
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reveals regions of deletions commonly found on cytogenetic analysis of AML i. e. del(5)(q), 
del(7)(q), -7 and del(20)(q). Another recurrent deletion was on chromosome 18, which occurred 
in two samples. One patient had a deletion of 17p that included the TP53 locus, which is 
sometimes observed in AML and MDS. 
IIIIs 
lý III ýý ýI 
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Figure 5.3 Map of DNA copy number by chromosome location. 
Green represents deletions, red represent copy number gains. Note the deletions are either 
smaller than 30 SNPs or include some heterozygous calls, so were not included in figure 2. 
Details of each abnormality are in Table 5.2. 
Recurrent copy number gains occurred on chromosomes 8,13 and 12. Trisomies of 
these chromosomes are well recognised in AML (NCI and NCBI 2001). Gain of the short arm 
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of chromosome 1 was seen in two patients. The cytogenetic abnormality add(1p36) has been 
recurrently observed in AML (National Cancer Institute 2006) and this locus is included within 
this region. 
5.3.3 Additional abnormalities discovered by SNP array, compared to cytogenetic analysis 
Normal karyotype (NK) AML samples are an obvious starting point for discovering 
additional abnormalities. There were 39 NK AMLs, of which 17 had 22 new abnormalities. 
Nineteen of these abnormalities were UPDs, 8 being telomeric and 11 being interstitial. 
Amongst the NK AML samples there were also 2 deletions and one region of copy number gain 
detected by SNP array. 
Balanced translocations involve no net loss or gain of DNA so cannot be detected by 
SNP array. However there were 6 new abnormalities that were detected in 15 patients with 
translocations; 5 were UPDs and one was a deletion of 7q associated with a patient with 
t(10; 11). One of the UPDs extended to the telomere, involving l lp and the WTI locus, in an 
AML with t(15; 17). Twenty AML samples had numerical cytogenetic abnormalities i. e. 
chromosomal gains or losses. These samples had an additional 19 abnormalities identified by 
SNP array, with 6 UPDs (all interstitial), 5 deletions, and 8 copy number gains. 
One disadvantage of conventional karyotyping, is that it requires dividing cells to be 
able to analyse them in metaphase. If the cells die or fail to grow on culture then there will be 
no result. Thirteen samples had no karyotype information. By SNP array, 7 abnormalities were 
detected in 6 of these AML samples; 2 were deletions and 5 were UPDs. 
A few abnormalities discovered by cytogenetic analysis were not found on SNP array 
analysis, i. e. patients 513,551 and 692. In some cases this could be due to rearrangements that 
involve no copy number change (e. g. der(4)(p) in patient 692), and in others there may have 
been a rare clone with the identified cytogenetic abnormality. The SNP array can only detect 
copy number changes in the majority clone, because it analyses DNA altogether. 
In summary, the SNP arrays were able to identify more abnormalities than conventional 
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karyotyping, although cytogenetic analysis complemented SNP array analysis by identifying 
balanced translocations and minor clones. UPDs were discovered in several different classes of 
cytogenetic abnormality, but were most often observed in NK AML. 
5.4 Discussion 
The map produced from this pilot set of data validates the use of SNP arrays to discover 
new regions with recurrent UPDs. UPDs were identified in 32% of patients (28 patients), which 
is a little higher figure than the original study. However, only by increasing the number of 
patients in this study can a more accurate assessment of the prevalence of UPD in AML be 
made. 
The map is validated by the detection of known cytogenetic abnormalities in AML. It 
can therefore be assumed that new abnormalities are likely to be genuine. There are recurrent 
regions of UPD that were observed in the previous study, i. e. UPD 13q, 11 p and 11 q. Other 
UPDs previously described, 6p, 9p, 19q and 21 were not present suggesting they may be less 
frequent. However many additional UPDs are seen in this study, particularly the interstitial 
UPDs. For larger regions such as 2p, 2q, 7q and 16q, it is unlikely that these would be germline 
abnormalities. However, some of the smaller regions may be homozygously inherited long 
haplotypes, particularly those at the centromeres. The remission samples show that homozygous 
regions can be inherited and acquired. The only way to identify recurrent inherited regions of 
homozygosity would be to analyse data from high-resolution SNP arrays on a population of 
normal individuals. Some large studies have been performed using SNP arrays to look at 
haplotype structure (International HapMap Consortium 2005) and structural variation in the 
human genome (Redon, et a! 2006), but not yet from the point of view of identifying regions of 
homozygosity, and not yet with sufficient individuals to identify recurrent regions. 
Given the results from the previous study, it seems likely that UPD of chromosome 13 
will be associated with a homozygous FLT3 ITD mutation and UPD of l lp will be associated 
with a homozygous WT1 mutation. Although the regions of homozygosity are all large, other 
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regions of UPD may also encode homozygous mutations. With a larger study, it may be 
possible to identify minimal regions of homozygosity to narrow down the region that contains 
the gene of interest. This study has now been completed with over 450 AML samples genotyped 
(Gupta, et a! 2008). 
Because FLT3 mutations have important prognostic implications, it will be interesting 
to see if any of the homozygous mutations have prognostic importance. However, the numbers 
of individual types of UPD is relatively small (only 3.5% for UPD13), therefore a large number 
of samples will be required to detect a statistically significant difference in survival. Given a 
10% difference in survival between FLT3 ITD positive and negative patients at five years, one 
might anticipate a smaller difference between heterozygous and homozygous FLT3 ITD 
mutations, which will make this difficult to demonstrate. 
If the prevalence of heterozygous and homozygous FLT3 ITD mutations is known, one 
may be able to predict the overall prevalence of other mutations with UPD. If one assumes the 
rate of mitotic recombination is constant for all mutations (which it may be if there is a 
physiological background rate) then by knowing the prevalence of homozygosity, the 
prevalence of heterozygosity can be calculated. This would not work if there is more than one 
mechanism leading to homozygosity, e. g. non-disjunction and mitotic recombination. This may 
be useful where the underlying gene is unknown. 
UPDs were seen in all the cytogenetic groupings, although there were a larger number 
in NK AML patients. With a lack of cytogenetic abnormalities, NK AML patients have only 
single gene defects, although there are likely to be many as yet unidentified genetic 
abnormalities e. g. microdeletions or amplifications. Given the association of acquired UPD with 
single gene mutations, it is perhaps not surprising that NK AML patients would have more 
UPDs, and mitotic recombination will of course maintain a normal karyotype. 
Several genetic changes other than UPD were found that were not observed by 
cytogenetics. Some of these e. g. loss of chromosome 7 or 20q, would have conferred a poor 
prognosis on these patients. SNP arrays therefore have the potential to identify prognostically 
important cytogenetic abnormalities. With higher resolution arrays now available (over 1 
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million loci across the genome), this opens up the possibility of identifying even smaller 
somatic changes. The system is robust, using only small amounts of DNA, does not require live 
cells, unlike expression profiling, and is complementary to cytogenetics in identifying complex 
rearrangements. It therefore has a potential clinical use, and if UPD is found to be of prognostic 
value this would increase the need to apply this technology to the diagnostic workup of AML. 
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Chapter 6 
Segmental UPD is a commonly acquired genetic event in relapsed 
AML 
6.1 Introduction 
AML is an aggressive hematological malignancy characterized by a proliferation of 
immature myeloid cells. Dramatic advances have been made over the last 40 years in the 
treatment of AML such that approximately 30% of those presenting under the age of 60 years 
can be cured with initial therapy. Complete remission, determined clinically, morphologically, 
immunologically and sometimes at the molecular level is reliably reported to be achieved in up 
to 80% of patients in this age group (Hann, et al 1997), but despite this success, re-emergence 
of leukemia is the rule rather than the exception. The 5 year relapse rate is 50% for patients less 
than 60 years, and increases to 80% in the over 60s (Goldstone, et al 2001, Grimwade, et al 
1998). Registry data from our institution similarly demonstrates that recurrence occurs in two- 
thirds of those achieving first complete remission. The prognosis of relapsed AML is dismal, 
with only 20% of patients surviving at 4 years (Milligan, et al 2006). 
Relapsed leukemic cells are characteristically resistant to chemotherapy. AML classified as 
poor risk by cytogenetic profile often has in vitro resistance to one of the most important 
chemotherapeutic drugs, cytosine arabinoside, which may explain the high risk of relapse 
(Zwaan, et al 2000). However, the underlying pathological mechanisms leading to relapse are 
poorly understood. The main pointers towards reasons for relapse are the numerous clinical and 
biological prognostic risk factors. Clinical features such as increasing age, high white cell count 
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at diagnosis and an initial failure to respond to chemotherapy are established poor risk factors. 
The amount of residual disease after chemotherapy also increases the risk of relapse. 
Cytogenetic abnormalities are the most important biological factor in predicting risk of 
relapse, as detailed in chapter 1, but only three case series have reviewed cytogenetic changes at 
diagnosis and relapse (Estey, et al 1995, Garson, et al 1989, Kern, et al 2002). Frequently, 
karyotypic abnormalities present at diagnosis were the same at recurrence, and no consistent 
cytogenetic abnormalities were acquired on the return of the AML. Therefore, it is not clear 
what role acquired karyotypic abnormalities play in the pathogenesis of relapse. 
Single gene mutations can also predict for risk of relapse, with FLT3 internal tandem 
duplication (ITD) being an important predictor of poor prognosis (Kottaridis, et al 2001). FLT3 
ITD, observed at diagnosis, can be increased in the level of DNA to above 50% in some cases, 
suggesting the mutation may have become homozygous (Kottaridis, et al 2002). Homozygous 
single gene mutations do occur in AML and these are associated with mitotic recombination or 
possibly a non-disjunction event leading to acquired uniparental disomy (UPD) (Fitzgibbon, et 
a! 2005). This suggests a mechanism for relapse in AML in which a heterozygous mutation is 
followed by a recombination event leading to homozygosity and clonal evolution. To evaluate 
this possibility, this study used 27 paired diagnosis and relapse AML samples, and array-based 
genome-wide mapping to identify regions of segmental UPD, with further mutation analysis. 
6.2 Methods 
6.2.1 Sample Selection 
Sufficient diagnostic and relapse blood and bone marrow samples for analysis were available 
from 27 patients with AML. Ethical approval was obtained and samples stored as detailed in 
Chapter 2. Because samples were chosen based on their availability, there was a bias towards 
samples with relatively high white blood cell counts (WBC). Patients presented between April 
1983 and September 2004. Patient demographics are shown in Table 6.1. Median age was 51 
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(range 35 to 68) years; 18 were male and 9 female. The median number of days to relapse was 
179 (range 88-758) days. The median overall survival of this group of patients was 1 year, 
which was inferior to those of all patients that had relapsed presenting to St. Bartholomew's 
Hospital during this period (1.5 years, p=0.001). Standard cytogenetic analysis was performed 
using bone marrow or peripheral blood. Metaphase preparations were harvested, and Giemsa 
banding was performed (Czepulkowski, et al 1992). Patient karyotypes were described 
according to the International System for Human Cytogenetic Nomenclature (Mitelman 1995). 
By MRC criteria (Grimwade, et al 1998), at diagnosis two patients had a favorable risk 
karyotype, twenty had intermediate risk karyotypes, one had a poor risk karyotype and two were 
unknown. 
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Table 6.1 Demographic data 
Patient 
Sample number 
Sex 
Age at FAB Presentation WBC, 
Diagnosis Remission diagnosis type x 109/1 
1 GSM173388 GSM173415 F 25 M5 89.0 
2 GSM173389 GSM173416 M 47 M1 182.0 
3 GSM173390 GSM173417 F 60 M2 10.4 
4 GSM173391 GSM173418 M 27 M1 65.9 
5 GSM173392 GSM173419 M 35 M4 79.7 
6 GSM173393 GSM173420 F 67 M5 127.2 
7 GSM173394 GSM173421 M 61 M4 11.3 
8 GSM173395 GSM173422 F 47 M2 53.1 
9 GSM173396 GSM173423 F 47 M4 88.1 
10 GSM173397 GSM173424 F 41 M1 9.0 
11 GSM173398 GSM173425 M 47 M1 90.0 
12 GSM173399 GSM173426 M 68 M2 19.8 
13 GSM173400 GSM173427 M 59 M1 88.4 
14 GSM173401 GSM173428 M 64 M4 31.2 
15 GSM173402 GSM173429 M 48 M5 33.2 
16 GSM173403 GSM173430 F 36 M4 30.7 
17 GSM173404 GSM173431 F 65 M1 4.4 
18 GSM 173405 GSM173432 M 52 M4 5.5 
19 GSM173406 GSM173433 M 52 M2 11.3 
20 GSM173407 GSM173434 M 46 M4 127.2 
21 GSM173408 GSM173435 M 43 M4 11.4 
22 GSM173409 GSM173436 M 61 M2 29.1 
23 GSM173410 GSM173437 M 50 M4 5.7 
24 GSM173411 GSM173438 F 65 M1 6.2 
25 GSM173412 GSM173439 M 25 M5 96.8 
26 GSM173413 GSM173440 M 21 M5 51.8 
27 GSM173414 GSM173441 M 43 M5 43.6 
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6.2.2 10K GeneChip Assay 
This was performed as previously described in Chapter 2. The data discussed have been 
deposited in the National Cancer Biotechnology Information (NCBI) Gene Expression Omnibus 
(GEO)(2005) and are accessible through GEO Series accession number GSE7210. Analysis of 
the call and copy number data was performed using GOLF. Regions of LOH were determined 
by comparing diagnostic and relapse samples. SNP copy number analysis identified these 
regions as being deleted, gained or as being disomic (Bignell, et a! 2004). SNP and gene 
annotatations used NCBI genome build 35. 
6.23 Mutation analysis 
Mutation screening was done for the entire coding region of CEBPA (Snaddon, et al 
2003) and specific exons of FLT3 (exons 14-15 and 20) (Abu-Duhier, et al 2001, Kiyoi, et at 
1999) as described in Chapter 2. 
PCR products were sequenced directly by use of an ABI 377 DNA sequencer (PE 
Applied Biosystems, Foster City, CA). Unincorporated primer was removed by ultrafiltration 
using a Centricon YM-100,000 filter device (Millipore). Sequencing data were analyzed using 
4Peaks (Griekspoor and Groothuis 2005). 
Fragment analysis of FLT3 exon 14-15 PCR products was performed using the same 
conditions but using QIAGEN Multiplex PCR kit, and measured by capillary electrophoresis 
using an ABI Prism 3700 Genetic Analyser (PE Applied Biosystems). Fluorescence signals 
were analysed using Genotyper 3.7 software (PE Applied Biosystems). 
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63 Results 
6.3.1 Clonal evolution of segmental UPD at relapse 
Clonal evolution resulted in segmental UPD and a homozygous mutation at relapse but not 
present in the paired diagnostic sample in about 40% (11/27) of cases. The most common 
abnormality detected was segmental UPD of chromosome 13 in 6 of 27 patients (22%) (Table 
5.1). The size of UPD varied from about 88Mb including the telomere, to the whole 
chromosome (114Mb). Copy number analysis revealed two copies of chromosome 13 across the 
region of LOH, excluding the possibility of a hemizygous deletion and included the locus for 
FLT3. Sequencing of FLT3 showed an ITD mutation, which was heterozygous at diagnosis and 
homozygous at relapse in all six cases (Table 6.3 and Figure 6.1). The mutations were identical 
at diagnosis and relapse in each case, demonstrating that the second clone had evolved from the 
initial leukemia. 
Patient 16 acquired segmental UPD of 19q at relapse, and was associated with a mutation of 
CEBPA located within the region of homozygosity. This mutation was also heterozygous at 
diagnosis and homozygous at relapse. The mutation, 207 C-'T (Genbank accession Y11525), 
created a stop codon which results in a truncated protein (Snaddon, et a! 2003). A further 
segmental UPD was acquired at 4q in patient 21. There is likely to be an associated 
homozygous mutation in the region of UPD, but in view of the large region involved (104Mb), 
this was not investigated further. 
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Table 6.3 Associated mutation and acquired segmental uniparental disomy (UPD) or loss of 
call (ITD, internal tandem duplication). 
Patient Segmental UPD acquired at Associated Mutation Status 
relapse Diagnosis Relapse 
1 Loss of call whole 13 FLT3 ITD heterozygous FLT3 ITD heterozygous 
4 13q FLT3 ITD heterozygous FLT3 ITD homozygous 
7 Loss of call whole 13 D835Y heterozygous D835Y homozygous 
9 13q FLT3 ITD heterozygous FLT3 ITD homozygous 
10 13q FLT3 ITD heterozygous FLT3 ITD homozygous 
14 Loss of call whole 13 D835Y heterozygous FLT3 wild type 
16 19q CEBPA 207 C-'T 
heterozygous 
CEBPA 207 C-ºT 
homozygous 
17 Whole 13 FLT3 ITD heterozygous FLT3 ITD homozygous 
19 13q FLT3 ITD heterozygous FLT3 ITD homozygous 
21 4q Unknown Unknown 
25 13q FLT3 ITD heterozygous FLT3 ITD homozygous 
63.2 Subclones with segmental UPD 
Three of the eleven patients (1,7 and 14) acquired UPD of chromosome 13 at relapse as 
defined by LOH with no change in copy number. However, they were distinguished from the 
other six cases with acquired UPD of chromosome 13 because their heterozygous calls did not 
become homozygous, but instead became no-calls. To understand how this may occur, a 
rudimentary understanding of the SNP calling algorithm is required. The Affymetrix 10K SNP 
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array uses an algorithm that compares the relative allele signal (RAS) from each allele on the 
forward and reverse strands (RAS1 and RAS2 respectively) to determine heterozygosity or 
homozygosity for individual SNPs (Liu, et a! 2003). No-calls are made when the RAS values do 
not determine the allele. If a proportion of cells within a sample are heterozygous and a 
proportion is homozygous at a given SNP locus, then the algorithm will be unable to assess 
homozygosity or heterozygosity and report a no call. Patients 1,7 and 14 each had a high 
frequency of no-calls along chromosome 13 at relapse. 
Figure 6.2 A. Change in relative allele signal (RAS) values between diagnosis and relapse, for 
SNPs heterozygous at diagnosis in the region of LOH on chromosome 13 for patient 1 and 9. B. 
Electropherogram demonstrating PCR fragment quantitation of FLT3 wild type, at 329 bp and 
the larger ITD fragment in patients 1 and 9. 
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Chapter 6 
Figure 6.2A displays the RAS values for patient 9 who has conventional LOII due to UPD, 
compared to patient 1. For patient 1, the RAS values are observed to move towards the values 
for homozygosity, but insufficiently, and therefore the SNPs are reported as no-calls. This 
demonstrates that the no-calls are due to a change in the proportion of alleles. The allele call 
rates for all other regions were greater than 90%, confirming that the no-calls were not due to a 
failure of hybridization. These AML samples all had a high blast percentage (>70%), so it is 
unlikely that normal germline contamination would have affected the SNP genotypes(Lindblad- 
Toh, et al 2000). The results most likely represent a mixture of homozygous and heterozygous 
leukemic cells. Both patient 1 and 9 had FLT3 ITD mutations within the region of UPD, hence 
to corroborate this evidence, PCR fragment analysis for FLT3 was performed (Figure 6.2B). 
Consistent with the SNP array results, patient 1 demonstrated a mixture wild type and mutant 
FLT3, but with a low level of ITD compared to wild type at diagnosis and a higher level of ITD 
at relapse. Patient 9 demonstrated almost loss of wild type FLT3 consistent with a homozygous 
ITP mutation as would be expected from acquired UPD. The conclusion drawn is that in patient 
1, a subclone of AML cells had acquired segmental UPD of chromosome 13 and a homozygous 
FLT3 ITD mutation. 
Patient 7 had a FLT3 loop mutation (D835Y), which became homozygous at relapse. Patient 
14 had a heterozygous D835Y mutation at diagnosis but lost this mutation at relapse. We 
hypothesize another unidentified mutation is present in the subclone with UPD of chromosome 
13 in this patient. 
63.3 Other copy number changes at relapse 
Altogether, 18 patients had LOH and copy number changes at relapse (Table 6.2). There 
were no consistently acquired karyotypic abnormalities at relapse, and only one patient acquired 
karyotypic changes at relapse that are reported to confer a poor prognosis at diagnosis (patient 
17, deletions of chromosome 7q and 20q). Seven patients had no detectable changes between 
diagnosis and relapse. Patient 20 had a gain of chromosome lp at diagnosis that was lost at 
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relapse. 
Patient 24 had a rare clone with a deletion of 12p that would go undetected by SNP array. 
Patient 15 also had cytogenetic changes undetected by SNP array, but the cytogenetic 
abnormalities were found in the dominant clone. We hypothesize that the dominant leukemic 
clone had a normal karyotype, but did not grow on short-term culture for karyotypic analysis. 
63.4 Chromosomal abnormalities at diagnosis (Table 6.2) 
Most of the regions of deletion and gain were confirmed by cytogenetic analysis. Those not 
confirmed were deletions that were either too small to be seen on cytogenetic analysis, or were 
regions of uniparental disomy (UPD). Regions of whole chromosome gain were also seen that 
corresponded with trisomy in the karyotype. Patients 8,14,17 and 24 had balanced 
translocations that cannot be detected by SNP array. 
There were four regions of UPD at diagnosis, one that was confirmed to be acquired from 
genotype analysis of the remission sample (patient 13), and another had homozygosity for FLT3 
ITD, indicating acquired UPD of 13q (patient 8). The other UPDs were much larger and not 
reported as large haplotypes blocks in the HapMap (International HapMap Consortium 2005), 
suggesting they are due to mitotic recombination, although homozygosity across the centromere 
of chromosome 11 (patient 12) is probably germline because of a lack of meiotic recombination 
near centromeric regions. 
6.4 Discussion 
This study has revealed the importance of acquired UPD in relapsed AML. Acquired 
segmental UPD resulted in a homozygous mutation, most commonly involving chromosome 13 
with FLT3 ITD. Interestingly, previous studies have shown that loss of wild type FLT3 in the 
context of FLT3 ITD is a poor prognostic marker at diagnosis (Thiede, et a12002, Whitman, et 
a! 2001). At presentation, a higher level of FLT3 ITD on PCR fragment analysis of genomic 
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DNA also confers an increased relapse risk (Gale, et al 2005), and segmental UPD of 
chromosome 13 provides a mechanism for this increase. Acquired segmental UPD is the most 
consistent genetic change in relapse, therefore it is important step in disease progression. 
The FLT3 receptor is a homodimer that is activated by FLT3 ligand at the cell surface. The 
FLT3 ITD mutation constitutively activates the receptor leading to disregulation of intracellular 
cell signaling pathways (Griffith, et al 2004). One explanation for the advantage gained by a 
homozygous FLT3 mutation may be that a homodimer with two mutated proteins has more 
activity than if one part is wild type. Homozygosity of the FLT3 D835Y loop mutation at 
relapse lends further support to the hypothesis that loss of wild type leads to relapse. Loss of a 
loop mutation without an ITD mutation was also observed associated with acquisition of UPD 
of 13q at relapse. This suggests there may be mutations of FLT3 outside of the conventional 
regions, or alternatively, other mutated genes on I3q. Homozygous FLT3 mutations would be 
ideal candidates for tyrosine kinase inhibitors. Following acquisition of UPD of chromosome 
13, inhibition of FLT3 may be an effective method of treating relapse in conjunction with other 
therapy, or a method of preventing relapse if used as maintenance after consolidation 
chemotherapy. 
Biallelic mutations of CEBPA are well recognized in AML, and are occasionally 
homozygous (Lin, et al 2005). Although a biallelic mutation is not a prerequisite for AML, it is 
important in its development, as demonstrated in familial cases of AML in which a germ line 
CEBPA mutation is followed after a long latency by a second CEBPA mutation and 
subsequently develops AML (Smith, et al 2004b). AML patients with mutations of CEBPA 
have a relatively good prognosis (Leroy, et al 2005). In this study, evolution of a homozygous 
CEBPA mutation was associated with relapsed AML, but further studies will be required to 
discover if homozygous CEBPA mutations have any prognostic implications. 
Mitotic recombination or non-disjunction leads to segmental or whole chromosomal UPD 
respectively. It is unknown whether these events occur before, during or after treatment. A rare 
subclone may be present in the initial population at diagnosis, but this would be extremely 
difficult to detect given the small proportional change in alleles that would result. In favor of 
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this theory, there are in vitro studies on mouse fibroblasts and normal human lymphocytes that 
have shown a physiological background rate of mitotic recombination of about 1 in 100 000 
cells (de Nooij-van Dalen, et al 1997). The alternative is that mitotic recombination occurs after 
exposure to cytotoxic chemotherapy, due to an increased rate of DNA double strand breaks. The 
relapse clone would then arise during or shortly after treatment, leading to a short time to 
relapse. With this small study it was not possible to make statistical comparisons in the time to 
relapse between those acquiring UPD at relapse and the rest of the AML patients. 
When segmental UPD clonally evolves at relapse, it infers that there is a proliferative 
advantage gained by the cell from the homozygous mutation. One model for clonal selection 
suggests that these cells are already present at diagnosis, and exhibit drug resistance, surviving 
through chemotherapy. The alternate model is that a leukemic stem cell, which is intrinsically 
more resistant to chemotherapy than differentiated cells, escapes chemotherapy induced death 
and subsequently undergoes mitotic recombination. 
The evolution of subclones with segmental UPD, seen here in three cases, is consistent with 
the clonal heterogeneity often seen with cytogenetic abnormalities in AML. Indeed, clonal 
heterogeneity is a feature of many cancers (Merlo, et al 2006). It raises the possibility that 
segmental UPD is under detected, since a low proportion of homozygous cells cannot be 
observed using SNP array technology, and as discussed above, low levels of segmental UPD at 
diagnosis would have the potential to lead to relapse. 
The frequency of acquired segmental UPD at diagnosis is 15-20% (Gorletta, et al 2005, 
Raghavan, et al 2005) and this study appears to demonstrate an increased frequency of UPD 
(40%). The study is limited by being a retrospective sample set and does not represent all 
subtypes of AML. However, it is still clear that mitotic recombination is an important means of 
disease progression. The phenomenon has been observed in one case of childhood AML 
involving FLT. ITD (Bungaro, et al 2006), and in a further case of a WT1 mutation (Nyvold, et 
al 2006). Several other cancers have demonstrated acquired UPD at diagnosis (Andersen, et a! 
2007, Teh, et al 2005), and these may also progress by mitotic recombination. Although 
segmental UPD of 13q is the commonest abnormality described here, further studies into 
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acquired segmental UPDs will reveal other targets in the treatment of AML and other cancers. 
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Discussion 
This study has used a new technology, microarray based genotyping, to demonstrate the 
importance of an old concept, mitotic recombination. The observation that acquired UPD is a 
frequent finding in AML, and its association with homozygous mutations, particularly at disease 
recurrence, gives an insight into the natural history of the progression of AML. 
7.1 Genotyping arrays, cytogenetic analysis and copy number 
Unlike many studies using aCGH or SNP arrays looking at copy number in solid 
tumours, in AML it is fortunate that a karyotype is available. Comparison can then be made 
with the expected copy number changes. Interpretation of deletions and gains could then be 
made. For example, patient 69 had trisomy 3 and 10 and the copy number ratio graph shows an 
increase compared to the line representing a copy number ratio of one (Table 3.3). 
These interpretations are particularly useful where there is more variability or noise. 
Firstly, SNP genotyping tends to be noisier in interpreting copy number at any individual SNP 
compared with aCGH because the size of the oligomers is so much smaller (25 nucleotides 
compared with several kilobases) leading to variation in hybridisation. Secondly, where a 
sample was processed with its germ-line remission, the kinetics of the PCR are similar, leading 
to a more comparable ratio. Thirdly, comparing like with like (i. e. AML to germ-line) is 
preferable to having to compare against a bank of normal DNAs. The kinetics of the PCR 
136 
Chapter 7 
between germ line and leukaemia are much more similar for a single individual; as others have 
noted, there are differences in the amplification of genomic regions, because of differences in 
the GC content of each region (Nannya, et a! 2005). If there was no available remission sample, 
then a bank of normal DNAs was required, to reduce the effects of copy number 
polymorphisms, although these have more implications for higher resolution genotyping arrays 
i. e. 250K than 10K arrays. 
Although G-banding can identify gross chromosomal abnormalities, small 
abnormalities cannot be detected. Such small deletions are seen in patient 78 at 5p, in patient 53 
at lp, and in patient 23 at 7q. The median inter-SNP distance on the 10K array is 113kb 
(Affymetrix 2003), so LOH of even a few SNPs can cover a megabase, and involve several 
genes. Recent studies using higher resolution arrays in ALL have demonstrated recurrent 
microdeletions involving genes of B cell development e. g. PAX5, amongst others (Mullighan, et 
a! 2007). It is likely many more of these microdeletions will be discovered in AML when using 
higher resolution arrays, and the pattern of genes involved may reveal much about the 
pathogenesis of AML. 
Other abnormalities are coincident with described karyotypic abnormalities, but suggest 
more complexity in the rearrangement. For example, GSM 173409 had a derivative chromosome 
9, with additional material and a translocation with chromosome 8. However, the array shows a 
deletion of part of the short arm of chromosome 9, giving more information as to the nature of 
the rearrangement. Similarly, patient 34 has a deletion of the whole of chromosome 7 by 
cytogenetic analysis, but the array shows part of the long arm of the chromosome adjacent to the 
centromere is retained. The remaining part was found by FISH on a marker chromosome. Small 
chromosomal aberrations such as these are difficult to see by conventional cytogenetic analysis, 
but the SNP array genotyping makes a useful tool to identify complex chromosomal 
rearrangements. 
7.2 UPD and homozygosity 
Mitotic recombination is a well recognised concept; one of the initial descriptions was 
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of its association with twin spots occurring in the fruit fly, Drosophila melanogaster (Stem 
1936). The fruit flies were heterozygous for genotypes that could cause phenotypic changes in 
skin colour and hair type, but had mosaic spots whose phenotype was of the recessive genotype. 
Stem showed that a mitotic cross-over event had led to homozygosity for that genotype. A 
similar phenomenon is seen in some vascular skin naevi (Koopman 1999), where each adjacent 
spot is homozygous for a different gene that is on the same chromosome arm. 
In cancer, the recombination leads to outgrowth of one of the clones because of a 
selective advantage from an underlying homozygous abnormality. The homozygously mutated 
genes associated with acquired UPD in this study include CEBPA, WTI, FLT3 and RUNXI 
mutations. All of these were previously known to be mutated in AML (King-Underwood, et al 
1996, Smith, et a! 2005). This still leaves several examples of acquired UPD without a known 
associated mutation e. g. UPD 6p, 4q, 9p and l lq. It should not be overlooked that even if there 
is no mutated gene associated with these regions, it is still possible that there is an associated 
gene with altered transcription due to a homozygous epigenetic effect, e. g. promoter 
methylation. 
Identifying genes associated with UPD could be a difficult task. The regions of 
homozygosity are tens or hundreds of megabases long, so there are hundreds of potential target 
genes. However, it is notable that for the regions where the associated gene is known, the point 
of recombination is frequently less than 10-15Mb away from the gene, despite the region of 
LOH being several times larger than this (an example of this is seen in Figure 6.1). However, 
this is still a large region from which to identify a candidate gene. Another method for gene 
discovery would be to identify highly or lowly expressed genes in the region of interest, 
compared with a leukaemia without acquired UPD. Array based gene expression would make 
the analysis of a large number of genes in a region of LOH a practical proposition. However, it 
may be neither of these methods can identify a gene, and it may be left to future developments 
in high throughput sequencing to identify mutations in a region that is several megabases in 
length. Despite the difficulties, there are likely to be novel genes involved in the pathogenesis of 
AML in regions of acquired UPD. The completion and publication of a map of UPD in AML 
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samples from the national MRC trials should reveal common recurrent regions of UPD and 
regions that are more rare. One use for the map could be to prompt groups who have genes of 
interest within regions of UPD to investigate these further. 
7.3 Homozygous versus heterozygous mutations 
In this study, the main consequence of acquisition of UPD in AML was to 
homozygously inactivate a TSG or increase the gene dosage of an oncogene. Conventionally, 
regions of LOH have been thought to harbour TSGs, but in this study oncogenes, FLT3, and 
TSGs, CEBPA, RUNX1 and WTI have been found in regions of UPD. 
Both the ITD and TKD mutations of FLT3 are activating mutations that cause 
constitutive phosphorylation of the receptor. Homozygosity increases the gene dosage in AML 
cells, suggesting that increased transcription of the mutant FLT3 causes more activation of the 
downstream cell-signalling pathway. However, the FLT3 ITD mutant receptor activates wild 
type FLT3 receptor as a heterodimer in AML cell lines (Kiyoi, et a! 1998), so it would appear to 
be unnecessary to have both alleles mutated. One could speculate that there are degrees of 
activation of the FLT3 receptor pathway, and a homozygous mutation may increase the pathway 
activation. 
CEBPA is a transcription factor that has two types of mutation in AML, both of which 
inactivate the protein. N terminal mutations cause deficient transactivation and are dominant 
negative in vitro, while C terminal mutations affect the zinc finger DNA binding domain (Pabst, 
et a! 2001). Frequently the mutations are biallelic, with one N- and one C-terminal mutation on 
each allele. These mutations can be seen in the context of CEBPA being a TSG. However, 
monoallelic heterozygous mutations are well recorded, as was seen at diagnosis in the case that 
acquired UPD19q at relapse. This suggests that there are varying degrees of inactivation of 
CEBPA and that there is a selective advantage for biallelic and homozygous mutations. 
RUNX1, another transcription factor, has also been described as a TSG. Mutations are 
found in its DNA binding domain, indicating loss of function. In familial platelet disorder, it 
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causes haploinsufficiency, as there is only a single allele affected (Song, et al 1999), but in de 
novo AML, especially FAB type MO, there are frequent biallelic mutations (Roumier, et a! 
2003, Roumier, et al 2006, Silva, et al 2003) (although the example in this study had FAB M2). 
Again, although a monoallelic mutation is sufficient to lead to AML, in some circumstances, a 
biallelic mutation is selected for. 
WTI mutations were first described in association with Wilms' tumours. It is another 
transcription factor in which most mutations associated with AML are in its zinc finger domain, 
suggesting they would cause loss of function and reduce the expression of downstream 
transcription targets. Most mutations are heterozygous, implying the mutations cause 
haploinsufficiency (King-Underwood, et al 1996). Congenital heterozygous mutations of WT1 
in the same region cause renal diseases such as Denys Drash syndrome, also indicating that a 
haploid mutation is sufficient to cause disease (Gao, et a! 2004). However, a few homozygous 
mutations have been described in AML (Nyvold, et al 2006), as have been noted associated 
with acquired UPD l lp in this study. 
What is common amongst these mutations is that there is a difference in the effect of 
monoallelic and biallelic mutations on the leukaemic cell, so that at least in some AML samples, 
gene dosage confers a selective advantage. The implication is that for oncogenes and TSGs 
alike, the genes are not simply "on" or "off', but there are gradations, probably reflecting more 
or fewer downstream targets of the genes being affected. 
A graduated evolution of genetic abnormalities in a single pathway suggests an 
increasing dependence on that pathway by the leukaemic cell, a concept that has been termed 
oncogene addiction (Weinstein and Joe 2006). In vitro evidence for oncogene addiction comes 
from mouse models and cell lines in which over expression of an oncogene such as MYC 
induced T cell lymphomas and AML, but which regressed with MYC inhibition (Felsher and 
Bishop 1999). Further clinical evidence has been cited from CML, where targeting a single 
oncogenic protein, BCR/ABL, with the tyrosine kinase inhibitor imatinib has a marked clinical 
response (Kantarjian, et a! 2002). Furthermore, accelerated phase and blast crisis tend to be 
associated with imatinib resistance due to mutations in BCR/ABL (Talpaz, et al 2006), 
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demonstrating the importance of retaining this oncogenic pathway. 
However, for most forms of malignancy, including AML, the concept of addiction to a 
single pathway seems counter-intuitive. Combination chemotherapy affects more than one 
pathway and that has led to the improvement in treatment for AML and other malignancies. 
However, the evidence from this study suggests that in patients who acquire UPD at relapse, 
there is an increased dependence on the pathway associated with the homozygous mutation, 
implying targeting the pathway would be treat the recurrent AML. For one of these pathways, 
downstream of the FLT3 receptor, inhibitors are being used in clinical trials. Small phase 1/2 
trials of FLT3 receptor inhibitors have been tried with multiply treated, relapsed or refractory 
AML patients with FLT3 mutations (Smith, eta! 2004a, Stone, et a! 2005). Some of the patients 
have had a haematological response, but only a few obtain a complete remission. It is just as 
likely that other pathways are also involved in relapse, and discovering these will be critical to 
improve the targeted treatment of relapsed AML. 
7.3.1 Transgenic animal models of MR and homozygous mutations 
Further investigation of the functional difference between AML with homozygous and 
heterozygous mutations may require animal models. Conventional methods of insertional 
mutagenesis involve inserting several copies of a mutation into a cell, either of a cell line, or of 
an embryonic stem cell in order to create a transgenic animal. The wild type copy is retained 
and the mutant alleles could be inserted anywhere into the genome. This is more analogous to 
gene amplification of one allele, rather than the situation that occurs with single gene mutation 
with or without MR. 
A transgenic animal model of MR has been described using mouse embryonic stem 
cells (Liu, et a! 2002). In this experiment, two complementary halves of the HPRT gene (3'and 
5'), each in a cassette between two loxP sites, were targeted to the same allelic position of 
complementary chromosomes. Each part of the HPRT gene was non-functional without the 
other half. On addition of Cre recombinase, some cells would undergo mitotic recombination, 
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fusing the two halves of HPRT together. The cell colonies were selected for by growing them in 
HAT (hypoxanthine/aminopterin/thymine) medium, as cells with a complete HPRT gene would 
be resistant to HAT medium. The rate of mitotic recombination observed was between 7x10'3 
and 3.5x10, depending on the chromosomal location targeted. 
A similar system using mouse embryonic stem cells heterozygous for a TP53 mutation 
and using a constituitively active FLP recombinase has been used study the development of 
tumours in transgenic mice produced from the embryonic stem cells (Wang, et a! 2007). The 
tumours produced in these transgenic mice were homozygous for mutant TP53, demonstrating 
the originating cells had undergone mitotic recombination. In addition, an increased number of 
epithelial tumours were observed compared with transgenic mice that were heterozygous for 
TP53. Hypothetically, if a heterozygous mutant mouse model was created for one of the genes 
known in AML instead of TP53, i. e. FLT3, RUNXI, WTI or CEBPA, then the phenotypic effect 
of mitotic recombination on these genes could be observed. Although a transgenic FLT3 ITD 
mouse exists (Lee, et a! 2005), this involved random insertion of the mutant gene, which would 
not be practical for this type of experiment. 
7.4 Clonal evolution 
The generally accepted model of clonal progression of neoplasia is that there is a 
sequence of genetic or epigenetic changes each leading to a selective (growth) advantage to the 
neoplastic clone (Nowell 1976). Evidence for this model comes from colorectal tumours where 
a sequence of genetic abnormalities was seen in adenomas and adjacent carcinomas from 
patients with familial adenomatous polyposis (Vogelstein, et al 1988). In this study, with 
increasing histological grade of adenoma and carcinoma, an increasing percentage of tumours 
with RAS mutations, chromosome 18q deletions and chromosome 17p deletions were observed. 
This model predicts that it is the dominant clone, with the greatest selective advantage, 
that makes up the tumour. However, the development of oesophageal cancer shows much 
greater genetic heterogeneity than would be predicted by this model alone (Maley, et a! 2006, 
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Maley, et al 2004). Patients with Barrett's oesophagus, a premalignant condition, have an 
increased risk of developing the malignant form of disease, squamous carcinoma of the 
oesophagus. The patients were monitored by sequential biopsies of the squamous epithelium of 
the oesophagus. Increased clonal diversity in these biopsies, as defined by more regions with 
LOH, TP53 mutations or CDKN2A mutations, lead to an increased risk of developing 
carcinoma. This implies development of a malignant clone comes about on the background of 
clonal heterogeneity. It explains why more than one clone with slightly different karyotypes 
may be observed on cytogenetic analysis. It also explains why acquired UPD was observed as a 
subclone in some cases. Some of these genetic aberrations may be carrier or hitchhiker 
mutations, as has also been observed in Barrett's oesophagus (Maley, et a! 2004), however, 
recurrent aberrations are likely to be important in malignant progression e. g. acquired UPD 13. 
Given the heterogeneous genetics of tumour development, there are likely to be 
additional mutations or UPDs in rare clones during leukaemogenesis. These may be selected for 
by chemotherapy e. g. there is some evidence that FLT3 ITD mutations confer resistance to 
chemotherapy (Seedhouse, et a! 2006). One implication of this hypothesis is that if rare clones 
with acquired UPD are identified at diagnosis, this would predict for the subsequent relapse of 
these patients. 
An important aspect to acquired UPD is that its development occurs on the background 
of a prior gene mutation. Mitotic recombination (or non-disjunction) is therefore a stepwise 
progression in the development of the leukaemia. The current model of leukaemogenesis, in 
which there is a mutation preventing differentiation (class 1), followed by a mutation increasing 
proliferation (class 2) (Kelly and Gilliland 2002), although useful in classifying types of 
mutation, is likely to be simplistic in terms of the progression of the leukaemia. Mitotic 
recombination could be just one of a number of progressive genetic events leading to 
leukaemogenesis. Mouse models in which haematopoietic progenitors are transduced with 
CBFbeta-SMMHC (a class 1 mutation) and FLT3 ITD (a class 2 mutation) produce AML 3-5 
months after transplantation, suggesting further mutations are required during the latent period 
(Kim, et a! 2007). 
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7.5 Mitotic recombination versus non-disjunction 
Most of the examples of acquired UPD are partial, involving a chromosome arm, so the 
mechanism involved is mitotic recombination. Some appear to involve the whole chromosome 
e. g. chromosome 13, suggesting not recombination, but non-disjunction, i. e. a failure of the 
chromosomes to separate equally at mitosis, as the mechanism leading to UPD. However, the 
most telomeric SNP on the arrays is still several megabases from the telomere, so a 
recombination point close to the telomere cannot be ruled out. Meiotic recombination is thought 
to be more common close to the telomeres, because linkage disequilibrium is low in these 
regions (International HapMap Consortium 2005), but mitotic recombination may not 
necessarily occur in the same regions as meiotic recombination. AML cells are known to 
undergo non-disjunction, resulting in trisomic chromosomes. It is worth noting that the SNP 
arrays show an increased copy number but no LOH for these trisomies, implying non- 
disjunction, with both parental chromosomes retained. There were no examples where one of 
the parental chromosomes was reduplicated. This has also been noted in hyperdiploid ALL 
where several chromosomes are trisomic (Paulsson, et al 2005, Paulsson, et al 2003). It suggests 
the importance of retaining both parental chromosomes i. e. avoiding loss of imprinting (LOI), 
however, acquired UPD does result in LOI. LOI of genes, such as IGF2, has been associated 
with tumorigenesis in other malignancies such as colorectal cancer (Sakatani, et al 2005). 
Although imprinting was not important for UPD of 11 p, its role in other regions of UPD cannot 
be ruled out. 
AML also undergoes the opposite event i. e. monosomy, particularly for chromosomes 5 
and 7. Loss of chromosome 5 or 5q is associated with reduced expression of CTNNAI by 
methylation or histone deacetylation (Liu, et al 2007). In acquired UPD, both chromosomes 
appear to be identical. The only apparent difference between UPD and monosomy is copy 
number, implying an advantage in retaining a diploid karyotype. For genes such as CTNNAI, 
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whose methylation may be important in the pathogenesis of AML, mitotic recombination would 
an alternative to chromosome loss. There are likely to be many other genes whose epigenetic 
suppression is important in AML, and this approach has led to the use of demethylating agents, 
e. g. decitabine (Kantarjian, et a! 2007), and histone deacetylase inhibitors, eg. valproic acid 
(Kuendgen, et a! 2005), in MDS/AML. 
Some epigenetically suppressed genes will be in regions of acquired UPD, therefore 
depending on which allele becomes homozygous, their expression would be altered. 
Hypothetically, some of these genes may contribute to leukaemogenesis. However, one main 
advantage of acquired UPD over monosomy is the maintenance of a diploid genome, allowing a 
physiological expression level, because gene dosage affects expression level (Schoch, et a! 
2006). Genes that do not maintain a normal expression level in the region of UPD could be 
important in the pathogenesis of AML. 
7.6 The mechanism of mitotic recombination 
A crossover event during mitosis is not a physiological event, unlike during meiosis. It 
implies a DNA double strand break (DSB) has taken place and then an incorrect repair. There 
are two major processes in double strand break repair (DSBR), non-homologous end joining 
(NHEJ) and homologous recombination (HR) (O'Driscoll and Jeggo 2006). NHEJ is the 
predominant method of repair in mammalian cells, but is error prone because it involves the 
ligation of the ends without a template. However, it is quick and can occur at all stages of the 
cell cycle (Sengupta and Harris 2005). HR is much more accurate because it uses a template 
with a matching sequence for repair. There are two models for homologous repair; strand 
displacement annealing (SDSA) does not involve a crossover event, whereas the DSBR model 
has the possibility crossing over or not. Two 4-way DNA strand junctions are formed, known as 
Holliday junctions (HJs). Depending on how the His are resolved depends on whether a 
crossover event occurs. Crossovers are not unusual in eukaryotic systems, which are the most 
studied (Prado, et al 2003). In mammalian cells, if a double strand break is induced, it can be 
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repaired using the homologous chromosome by allelic recombination or gene conversion, 
causing LOH (Moynahan and Jasin 1997). Short and long tract gene conversion is seen, with the 
former involving only the gene, and the latter extending much farther downstream. This is a 
potential mechanism for the MR seen in AML. However, in mammalian cells DSBR by HR 
usually occurs by sister chromatid exchange (Sung and Klein 2006, Takata, et al 1998), which 
is at the G2/S phase of the cell cycle, rather than with the homologous chromosome. It has also 
been seen that although heterologous chromosomes with similar sequence can be used to repair 
DSBs, crossovers are markedly suppressed, to prevent translocations (Richardson, et al 1998). 
This suggests there are normally strong mechanisms to prevent chromosomal aberrations due to 
crossovers. 
Helicases are enzymes that can separate the two strands of a DNA double helix, and 
some are involved in regulating crossover in HR (Sung and Klein 2006). For example, BLM 
helicase is involved in resolving double Holliday junctions formed as an intermediary during 
DSBR by HR. Other helicases involved in HR have been described in yeast, e. g. sgs2, but their 
orthologues have not been found in mammalian cells. Congenital mutation of BLM leads to 
Bloom syndrome, an autosomal recessive disease. The children have a short stature, a 
predisposition to malignancy and photosensitivity (German 1997). Bloom syndrome is 
associated with an unstable karyotype, and the cells of these individuals have an increase in 
sister chromatid exchange as well as exchange between homologous chromosomes (Chaganti, et 
al 1974). A mouse model for Bloom syndrome also shows increased tumourigenesis and mitotic 
recombination (Luo, et a! 2000). One may hypothesise that AML patients with UPD have 
defects in BLM or other RecQ helicases, leading to a mitotic recombination event. However, 
one would expect cells with defects in HR to have very disordered karyotypes, and many of the 
AML samples had a normal karyotype. A polymorphism in the gene may confer a subtler 
defect, increasing the risk of DNA DSBs whilst maintaining karyotype stability. There is some 
evidence that polymorphisms in RADS1 (RAD51-G135C) and XRCC3 (XRCC3-24IMet) 
predispose to de novo AML and therapy related AML (Seedhouse, et al 2004). Both of these 
genes are important in HR and DSBR. RAD51 is of particular importance as it assembles onto 
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single stranded DNA to form a presynaptic filament, prior to searching for homologous regions 
in double stranded DNA (Sung and Klein 2006). It would be interesting to observe whether 
patients with these polymorphisms who develop AML are more likely to have acquired UPD. 
On top of inherited defects and polymorphisms in DNA repair, there are also acquired 
DNA repair defects that are prevalent in cancer cells. It has long been assumed that it is a 
prerequisite for cancer cells to have defects in DNA repair, which leads to the genetic instability 
observed in cancer. It has been proposed that the exposure to specific mutagens selects for cells 
with specific types of genetic instability (Breivik and Gaudernack 2004). Evidence for this 
comes from genetically stable colorectal cancer cell lines (Bardelli, et al 2001). Exposure of 
these cells to bulky-adduct-forming agents selects for cells with chromosomal instability i. e. 
gains and losses of chromosomes in subsequent generations. Conversely, cells from the same 
cell line selected after exposure to an alkylating agent develop microsatellite instability rather 
than chromosomal instability. The cells that survive in the presence of the mutagen no longer 
repair these DNA defects because it is time and energy consuming to do so. Therefore, they are 
able to proliferate, and although they accumulate mutations, as long as they are not deleterious, 
they will continue to proliferate. 
AML cells prior to acquiring UPD have a heterozygous mutation that probably confers 
a proliferative advantage. If the marrow environment additionally confers an advantage to those 
cells that acquire a defect in HR, then this will increase the chance of mitotic recombination. 
However, because there is a background rate of mitotic recombination, at least in vitro, it may 
not be necessary for any defect in HR to be present. One way to determine whether there is a 
difference in HR between AML with UPD and without would be to observe the frequency of 
sister chromatid exchanges (SCE) as a surrogate for HR. As with Bloom syndrome this would 
be increased if there were a defect in HR. However, previous studies have shown no difference 
in SCE between normal individuals and AML cells (Jones, et al 1992). The variation in SCEs in 
AML is small (0.4-1.8 per cycle) compared with the high number in Bloom syndrome (45-162) 
(Chaganti, et al 1974), therefore it is unlikely this method would find a difference, and again 
suggests if there is any variation in HR that it is subtle. 
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The implication from experiments on colorectal cell lines is that the environment of the 
bone marrow is important in the development of genetic and cytogenetic abnormalities in AML. 
AML patients with chromosomal instability, i. e. gains and losses will have different DNA repair 
defects from those with translocations, single gene mutations and UPD. Examples of this are 
seen in therapy related AML where patients exposed to alkylating agents are at risk of AML 
with del(7q) and have other karyotypic abnormalities associated with chromosome instability, 
and those exposed to topoisomerase II inhibitors are at risk of AML with MLL and other 
translocations, which are defects associated with DSBR. The characteristics of the environment 
leading to de novo AML are unknown, but the nature of their genetic abnormalities and the 
nature of any DNA repair defects may give clues. 
7.6.1 Breakpoints of mitotic recombination 
The sequence at the breakpoints of mitotic recombination may give a clue as to the 
nature of the DNA break involved. This has been particularly important for secondary AMLs 
where the patient has been exposed to cytotoxic agents that can cause DSBs. An example of this 
has been described in therapy related APML, where a8 base pair hotspot in PML was found to 
be the point of translocation, after exposure to mitoxantrone (Mistry, et al 2005). 
Fragile sites throughout the genome have been documented by them forming breaks on 
addition of aphidocolin, a DNA polymerase inhibitor. There may be characteristics of DNA 
sequence that cause regions of the genome to be fragile and lead to a tendency for DSBs 
(Glover, et al 2005). Rare, Mendelian inherited fragile sites are associated with repeat 
sequences, but the only consistent feature of common fragile sites is an increase in AT rich 
sequences. Some (but not all) of the breakpoints of UPD do lie in fragile sites, e. g. the 
breakpoints on llp associated with WTI mutations lie within the common fragile site FRA1IE 
at l1pl3. 
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7.7 Conclusions 
Much of the investigation of the pathogenesis of AML has, not surprisingly focussed on 
the primary mutations in leukaemogenesis. However, the acquisition of UPD is a secondary step 
in the development of AML. Cancer has been considered a multi-step genetic disease, and the 
investigation of acquired UPD demonstrates not only which mutations are important, but also 
how they progress at the presentation of AML and at recurrence. It can be used as a model for 
the multi-step pathogenesis of cancer, and therefore further investigation of UPD, particularly at 
relapse, may have implications for our understanding of how cancers and leukaemia in 
particular develop. 
However, mitotic recombination is only a mechanism in the development of the 
leukaemia, and it is the underlying homozygous mutation that is pathogenetic. The mutations 
are potential drug targets and markers for disease progression, and the discovery of novel 
regions of acquired UPD may reveal new targets and markers. 
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